{"meta":{"query_hash":"c4752fabaa7c","filters":{"venue":"BioDrugs"},"cohort_total":53,"direct_labels_cover":0,"predictions_cover":53,"exported":53,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/c4752fabaa7c","api":"https://metacan.xera.ac/api/v1/cohort?venue=BioDrugs"},"results":[{"id":"W137417466","doi":"10.2165/00063030-200519010-00005","title":"Antibody Induction Therapy in Renal Transplant Patients Receiving Calcineurin-Inhibitor Immunosuppressive Regimens","year":2005,"lang":"en","type":"review","venue":"BioDrugs","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Medicine; Basiliximab; Daclizumab; Thymoglobulin; Calcineurin; Immunology; Internal medicine; Transplantation; Gastroenterology; Tacrolimus","score_opus":0.04379392079459723,"score_gpt":0.35726717048229173,"score_spread":0.3134732496876945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W137417466","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005731601,0.99898976,0.000046939058,0.000069747024,0.000039029397,0.0000040562845,0.000008447221,0.0000018978672,0.00026686685],"genre_scores_gemma":[0.0053652925,0.99401265,0.0002009974,0.00014841763,0.00009553509,0.000011322262,0.00002910623,6.1164036e-7,0.00013590984],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.999736,0.000075254735,0.00006529359,0.000030670566,0.00007539201,0.000017355185],"domain_scores_gemma":[0.99931026,0.00043988056,0.00017464347,0.0000070493834,0.00004914802,0.000019008576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000679829,0.0004067334,0.0021383017,0.00096872274,0.00015536707,0.00045783978,0.0006726377,0.0005592044,0.0017217483],"category_scores_gemma":[0.0013116116,0.00015263568,0.00077655894,0.001128895,0.00018680927,0.00041756607,0.0002300281,0.00083550496,0.00027745686],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047275075,0.0001351576,0.0011221407,0.02663421,0.0005953075,0.00019088255,0.00003559355,0.00015929059,0.0007679659,0.00035344865,0.0052480893,0.9642852],"study_design_scores_gemma":[0.0028754696,0.004076436,0.06546751,0.09289498,0.01833106,0.012373936,0.00042699647,0.0009212319,0.005255967,0.0027261227,0.79450667,0.00014362048],"about_ca_topic_score_codex":0.00093094603,"about_ca_topic_score_gemma":0.0025226525,"teacher_disagreement_score":0.0021383017,"about_ca_system_score_codex":0.00036320763,"about_ca_system_score_gemma":0.00077555096,"threshold_uncertainty_score":0.0057597756},"labels":[],"label_agreement":null},{"id":"W1515001738","doi":"10.2165/00063030-200721020-00008","title":"Adalimumab in Crohn??s Disease","year":2007,"lang":"en","type":"article","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Adalimumab; Crohn's disease; Medicine; Pharmacotherapy; Disease; Internal medicine","score_opus":0.006292762627965007,"score_gpt":0.24144955538876453,"score_spread":0.23515679276079954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1515001738","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3152902,0.6265459,0.0014018536,0.018580677,0.0039170827,0.000067681045,0.00029303462,0.00015140366,0.03375215],"genre_scores_gemma":[0.88482183,0.0931327,0.0018574555,0.005128217,0.0021302574,0.000058462396,0.00032578158,0.000025451338,0.012519896],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982184,0.00007005581,0.000027108477,0.00001833188,0.000027739723,0.00003494804],"domain_scores_gemma":[0.99981505,0.000077724915,0.00002766205,0.000010919159,0.0000267316,0.000042038875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005285723,0.00025781337,0.000785258,0.00036435292,0.0003218214,0.00052813266,0.00019441974,0.0008342842,0.0022382757],"category_scores_gemma":[0.000524129,0.00009669044,0.00037485725,0.00025470633,0.00024731987,0.00028600972,0.00017634551,0.00088932255,0.0006154217],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023551585,0.00079212827,0.020437518,0.0015796799,0.00033387236,0.0053694802,0.00016389965,0.0006184487,0.019728137,0.004639903,0.013704767,0.90908045],"study_design_scores_gemma":[0.014262651,0.026618196,0.17983049,0.0021943722,0.003023327,0.03895502,0.000637233,0.0039671604,0.033307455,0.011033346,0.68602574,0.0001450485],"about_ca_topic_score_codex":0.00061036745,"about_ca_topic_score_gemma":0.0009700721,"teacher_disagreement_score":0.0022382757,"about_ca_system_score_codex":0.0004632995,"about_ca_system_score_gemma":0.00030601455,"threshold_uncertainty_score":0.007487774},"labels":[],"label_agreement":null},{"id":"W1778153929","doi":"10.1007/s40259-015-0144-3","title":"Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast","year":2015,"lang":"en","type":"review","venue":"BioDrugs","topic":"Phosphodiesterase function and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health","funders":"","keywords":"Apremilast; Psoriasis; Medicine; Proinflammatory cytokine; Pharmacology; Tumor necrosis factor alpha; Immunology; Tofacitinib; Phosphodiesterase; Inflammation; Psoriatic arthritis; Rheumatoid arthritis; Chemistry","score_opus":0.0367836431140947,"score_gpt":0.31696843569433947,"score_spread":0.28018479258024476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1778153929","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004769811,0.9730113,0.002714081,0.009276625,0.0015319041,0.00012546414,0.00014277901,0.0001126491,0.008315267],"genre_scores_gemma":[0.024064215,0.94227874,0.0053659314,0.012273765,0.0037262102,0.000164239,0.00039103098,0.000067582936,0.01166834],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975795,0.00005524136,0.000022245109,0.00006010592,0.00006920524,0.000035161196],"domain_scores_gemma":[0.99957174,0.00012595404,0.000060435428,0.000011028131,0.00014041878,0.0000904596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008518793,0.00085138873,0.0009809252,0.00090993824,0.00023691768,0.0008706644,0.000606529,0.0011857513,0.0044249883],"category_scores_gemma":[0.00048067304,0.0002558339,0.00056469487,0.0007068504,0.00040241753,0.001242854,0.00055534043,0.003948933,0.002502144],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009316137,0.0008926425,0.00046176714,0.005823447,0.00012787725,0.0009486573,0.00013264883,0.0004301,0.02366221,0.0059998743,0.06175725,0.89883196],"study_design_scores_gemma":[0.00082427385,0.0033419516,0.002404387,0.0017772692,0.00019513146,0.0038691396,0.00008346739,0.00064349954,0.00471328,0.0026613316,0.97942895,0.000057381512],"about_ca_topic_score_codex":0.0004427793,"about_ca_topic_score_gemma":0.0016850638,"teacher_disagreement_score":0.0044249883,"about_ca_system_score_codex":0.00042784758,"about_ca_system_score_gemma":0.00052124215,"threshold_uncertainty_score":0.014803052},"labels":[],"label_agreement":null},{"id":"W183087027","doi":"10.2165/00063030-200418050-00004","title":"Islet Transplantation in Patients with Diabetes Mellitus","year":2004,"lang":"en","type":"review","venue":"BioDrugs","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Immunosuppression; Transplantation; Azathioprine; Diabetes mellitus; Tacrolimus; Sirolimus; Type 1 diabetes; Insulin; Islet; Everolimus; Organ transplantation; Immunology; Intensive care medicine; Internal medicine; Endocrinology; Disease","score_opus":0.015294381505291369,"score_gpt":0.25792639036646875,"score_spread":0.2426320088611774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W183087027","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015743278,0.9989017,0.00008226886,0.00013955953,0.00017086754,0.0000022861004,0.0000061043947,0.000003594761,0.00053615065],"genre_scores_gemma":[0.0013153697,0.9976126,0.00013599018,0.00031240284,0.00026691455,0.0000048053284,0.000015727332,0.0000011173889,0.00033517834],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982446,0.000041183168,0.00003760413,0.000029246048,0.000052242285,0.000015278109],"domain_scores_gemma":[0.9995517,0.00027343174,0.0000847946,0.000011681523,0.000047978127,0.000030310548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065065,0.0008335913,0.0022203298,0.0017684789,0.00019492964,0.00084306515,0.0005693424,0.000877065,0.0029240754],"category_scores_gemma":[0.0009920171,0.00018685666,0.00068070256,0.001957653,0.00041330152,0.0009433608,0.00055890036,0.0015424737,0.0008577854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024708055,0.00007493929,0.00040008902,0.010801143,0.00014443783,0.00042486214,0.000025030093,0.00015402726,0.0005801691,0.0006373811,0.013095641,0.9734152],"study_design_scores_gemma":[0.0004239205,0.0006409472,0.0055272076,0.015331757,0.0018567826,0.0097329095,0.00017789898,0.00022361186,0.0011803104,0.0018527567,0.9630002,0.00005165837],"about_ca_topic_score_codex":0.0005843686,"about_ca_topic_score_gemma":0.0016320593,"teacher_disagreement_score":0.0029240754,"about_ca_system_score_codex":0.00032219006,"about_ca_system_score_gemma":0.000642402,"threshold_uncertainty_score":0.009782016},"labels":[],"label_agreement":null},{"id":"W1965655787","doi":"10.2165/00063030-200519010-00004","title":"Pharmacologic Approaches to the Treatment of Amyotrophic Lateral Sclerosis","year":2005,"lang":"en","type":"review","venue":"BioDrugs","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Riluzole; Amyotrophic lateral sclerosis; Glial cell line-derived neurotrophic factor; SOD1; Excitotoxicity; Neurodegeneration; Neurotrophic factors; Medicine; Oxidative stress; Neuroprotection; Pharmacology; Vascular endothelial growth factor; Glutamate receptor; Biology; Disease; Pathology; Cancer research; Internal medicine; Receptor","score_opus":0.5004309636387372,"score_gpt":0.4003231433586333,"score_spread":0.1001078202801039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965655787","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000104950974,0.9982931,0.00017887595,0.00018790069,0.00021692638,0.000010699905,0.000016940892,0.000009491268,0.0009811118],"genre_scores_gemma":[0.00049563806,0.9982443,0.00030466175,0.00021600498,0.00013392691,0.000011117525,0.000027031785,0.0000012587772,0.00056607684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981743,0.00003172082,0.000028896518,0.00003054707,0.00007331042,0.000018195664],"domain_scores_gemma":[0.99967957,0.00015692823,0.00005692808,0.000008825467,0.00006951109,0.000028314416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006651433,0.0013694318,0.0023584925,0.0029970447,0.00045943397,0.0010075023,0.0014024883,0.0013909221,0.0044072852],"category_scores_gemma":[0.00079149834,0.00039610892,0.00070565235,0.0024561489,0.000696149,0.0012223736,0.00065954926,0.002804972,0.0022280896],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019219035,0.00022123313,0.000100248886,0.013592979,0.00015465182,0.0002935686,0.000045742247,0.00038522473,0.0021244998,0.0028783719,0.030895421,0.9491159],"study_design_scores_gemma":[0.00017710887,0.00029987324,0.000804375,0.0050832247,0.00033855197,0.0015539676,0.00006493977,0.00014557844,0.0008872287,0.002028442,0.9885848,0.00003178147],"about_ca_topic_score_codex":0.00221468,"about_ca_topic_score_gemma":0.005361165,"teacher_disagreement_score":0.0044072852,"about_ca_system_score_codex":0.0006608967,"about_ca_system_score_gemma":0.0010717247,"threshold_uncertainty_score":0.014743865},"labels":[],"label_agreement":null},{"id":"W1976055108","doi":"10.2165/00063030-200317040-00006","title":"Meta-Analysis of Basiliximab for Immunoprophylaxis in Renal Transplantation","year":2003,"lang":"en","type":"review","venue":"BioDrugs","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"","keywords":"Basiliximab; Medicine; Transplantation; Internal medicine; Azathioprine; Placebo; Kidney transplantation; Gastroenterology; Surgery; Pathology","score_opus":0.1943935681286605,"score_gpt":0.39863552428444543,"score_spread":0.20424195615578494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976055108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017559519,0.9797642,0.0011899736,0.0002541678,0.00037014345,0.00013500024,0.00039746612,0.000042795655,0.0002866838],"genre_scores_gemma":[0.500989,0.49230504,0.0034520682,0.001050817,0.00057563087,0.00043505942,0.0005850469,0.000044877743,0.0005625405],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9918759,0.005249182,0.0013266847,0.00070275477,0.0006254772,0.00022002115],"domain_scores_gemma":[0.98729205,0.009734445,0.0018475206,0.0004272989,0.00050896825,0.00018977065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01175635,0.002694833,0.0150431665,0.001981598,0.00042993657,0.0015186549,0.0016103251,0.0015912872,0.0027754386],"category_scores_gemma":[0.020319378,0.0011938978,0.026488304,0.003023656,0.00048727292,0.00089440466,0.0009973538,0.001851276,0.0002102334],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01510432,0.0000489732,0.0042041056,0.0660398,0.8969124,0.0001112911,0.000039882612,0.00082610414,0.00028164906,0.000095154384,0.0006027228,0.015733691],"study_design_scores_gemma":[0.0028562164,0.0004884712,0.0027935507,0.0017960515,0.9905945,0.000071415176,0.000014884366,0.00019728897,0.00013820596,0.00011951514,0.00091634266,0.000013557668],"about_ca_topic_score_codex":0.0052229,"about_ca_topic_score_gemma":0.010289195,"teacher_disagreement_score":0.0150431665,"about_ca_system_score_codex":0.0018132222,"about_ca_system_score_gemma":0.0020919493,"threshold_uncertainty_score":0.06217426},"labels":[],"label_agreement":null},{"id":"W1983049039","doi":"10.2165/00063030-200822030-00002","title":"Developing Therapeutic Immunoglobulins","year":2008,"lang":"en","type":"review","venue":"BioDrugs","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Indigenous and Northern Affairs Canada","keywords":"Medicine; Immunology; Antibody; Thrombocytopenic purpura; Disease; Immune system; Internal medicine","score_opus":0.060472512308744834,"score_gpt":0.31447269742110623,"score_spread":0.2540001851123614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983049039","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00064752466,0.9935622,0.001322397,0.0005271941,0.0009080069,0.000022729362,0.000020087786,0.000024409339,0.002965401],"genre_scores_gemma":[0.005047941,0.9854196,0.0017631198,0.0013501031,0.00082066417,0.000061638864,0.00012579281,0.000008792073,0.00540228],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983394,0.00003532972,0.0000175713,0.00003079421,0.0000537532,0.000028632252],"domain_scores_gemma":[0.9998646,0.00006784409,0.000024488434,0.0000064998253,0.000022252234,0.000014330108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063189084,0.001107234,0.001197035,0.0012495891,0.00017751427,0.0007252196,0.00081304694,0.0015464659,0.0027573523],"category_scores_gemma":[0.0005166341,0.00027507212,0.00044466447,0.0007296208,0.0005743946,0.001137534,0.0006748662,0.0026450246,0.0015233082],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014307724,0.00012300375,0.00014978215,0.0048637306,0.000050405975,0.0005098223,0.00003886934,0.00048004853,0.0061892536,0.006296059,0.027613081,0.9535428],"study_design_scores_gemma":[0.00010335924,0.00017156378,0.00032647187,0.0012706482,0.00009360831,0.002474886,0.000026933933,0.00021844998,0.0032607545,0.002331995,0.9897076,0.000013865854],"about_ca_topic_score_codex":0.00037931855,"about_ca_topic_score_gemma":0.0006754967,"teacher_disagreement_score":0.0027573523,"about_ca_system_score_codex":0.00056825,"about_ca_system_score_gemma":0.00055752846,"threshold_uncertainty_score":0.009224236},"labels":[],"label_agreement":null},{"id":"W1989638496","doi":"10.1007/s40259-013-0072-z","title":"Interferon-Free Regimens for Hepatitis C: Combine and Conquer","year":2013,"lang":"en","type":"review","venue":"BioDrugs","topic":"Hepatitis C virus research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"European Association for the Study of the Liver; Genentech; Bayer HealthCare","keywords":"Telaprevir; Boceprevir; Medicine; Sofosbuvir; Pegylated interferon; Hepatitis C; Internal medicine; Daclatasvir; Hepatitis C virus; Dolutegravir; Interferon; Immunology; Ribavirin; Intensive care medicine; Viral load; Human immunodeficiency virus (HIV); Virus; Antiretroviral therapy","score_opus":0.12256526697449986,"score_gpt":0.4082298027057468,"score_spread":0.28566453573124695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989638496","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008868299,0.9991611,0.000075180775,0.00015515916,0.000097614284,0.000006093735,0.000008961047,0.0000034136626,0.00040381282],"genre_scores_gemma":[0.0007309592,0.9983181,0.00019078713,0.00030772152,0.00012010551,0.000008162005,0.000017695893,0.0000012024005,0.00030523687],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983335,0.000044964137,0.000027873562,0.00002592498,0.000051689185,0.000016120492],"domain_scores_gemma":[0.99968433,0.00020429236,0.000050195034,0.000007666331,0.000036279227,0.000017305812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007667026,0.00090251374,0.0018418947,0.0014971616,0.00020915215,0.00071110396,0.00082830247,0.0009960092,0.003638691],"category_scores_gemma":[0.0008254204,0.0002720161,0.0007038893,0.0013819949,0.00040020494,0.0011478706,0.0005494218,0.0019772057,0.0009783393],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016633906,0.00007239347,0.00008113734,0.014979099,0.00015885253,0.000071713956,0.000023666731,0.00019372611,0.00069795863,0.0016969868,0.014327152,0.9675308],"study_design_scores_gemma":[0.000363304,0.00041562834,0.0010798651,0.013885621,0.0009460996,0.0011561589,0.0000851014,0.00020998638,0.0007944053,0.003189889,0.9778331,0.000040898893],"about_ca_topic_score_codex":0.0008366777,"about_ca_topic_score_gemma":0.002513103,"teacher_disagreement_score":0.003638691,"about_ca_system_score_codex":0.00044913517,"about_ca_system_score_gemma":0.0006732556,"threshold_uncertainty_score":0.012172639},"labels":[],"label_agreement":null},{"id":"W1990941062","doi":"10.2165/00063030-200822040-00005","title":"Anti-Adhesion Molecule Strategies for Crohn Disease","year":2008,"lang":"en","type":"review","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Infliximab; Crohn's disease; Adalimumab; Medicine; Monoclonal antibody; Disease; Tumor necrosis factor alpha; Monoclonal antibody therapy; Inflammatory bowel disease; Immunology; Monoclonal; Certolizumab pegol; Antibody; Internal medicine","score_opus":0.025001312585896676,"score_gpt":0.3008105274606349,"score_spread":0.27580921487473825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990941062","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016510654,0.9971041,0.00044515214,0.00050337875,0.0006606504,0.000008528173,0.000016339112,0.0000137715,0.0010828804],"genre_scores_gemma":[0.001087478,0.995659,0.000738359,0.0005408295,0.000451858,0.00002093335,0.000042504293,0.0000031273985,0.0014559812],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998273,0.000031466596,0.000021467955,0.000027366696,0.000067255554,0.000025239407],"domain_scores_gemma":[0.9997255,0.00013806592,0.000030369349,0.000010100787,0.00006564906,0.000030234281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010083133,0.001168301,0.0017773346,0.0014601077,0.0003228145,0.0011498262,0.001232547,0.0017282508,0.0025736343],"category_scores_gemma":[0.00075676624,0.00037040547,0.00054090074,0.0012761549,0.00085453165,0.0014731208,0.00066046417,0.0038766132,0.0019647053],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023857185,0.00018327839,0.00013461364,0.0060000927,0.00010213049,0.0004122588,0.000046616977,0.0009019214,0.004669979,0.008803548,0.06498958,0.9135175],"study_design_scores_gemma":[0.00009000883,0.0001321697,0.00032309355,0.0009532929,0.000088457164,0.00092701876,0.000031699954,0.00017464564,0.0008924371,0.0027304054,0.9936407,0.000015981903],"about_ca_topic_score_codex":0.000780121,"about_ca_topic_score_gemma":0.00202128,"teacher_disagreement_score":0.0025736343,"about_ca_system_score_codex":0.00074425904,"about_ca_system_score_gemma":0.00066533353,"threshold_uncertainty_score":0.0086096525},"labels":[],"label_agreement":null},{"id":"W2007886942","doi":"10.2165/00063030-200013040-00004","title":"Use of Thalidomide in Dermatological Indications","year":2000,"lang":"en","type":"article","venue":"BioDrugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Thalidomide; Medicine; Adverse effect; Immunology; Pharmacology; Drug; Disease; Internal medicine; Multiple myeloma","score_opus":0.07712116623729452,"score_gpt":0.3360419291086052,"score_spread":0.25892076287131066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007886942","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6229297,0.31019664,0.004218441,0.003935994,0.00074920943,0.00013142673,0.00046092615,0.00014020968,0.057237465],"genre_scores_gemma":[0.95799744,0.033208076,0.0017087923,0.0009566848,0.00030546417,0.000039401708,0.00020401365,0.000019462559,0.005560619],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998467,0.000048468894,0.000013871535,0.0000182276,0.000044721615,0.000028029983],"domain_scores_gemma":[0.9997515,0.00010321195,0.000064645705,0.00001567827,0.00002716656,0.000037886763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033694188,0.00012691952,0.0003164339,0.0005486863,0.00029151814,0.00036164833,0.0001999984,0.00039372157,0.0025556316],"category_scores_gemma":[0.00077187666,0.000055246528,0.00037595487,0.00043623126,0.00015466423,0.00017216528,0.00016814104,0.00052426243,0.00041350684],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047709737,0.00077936123,0.033758868,0.0014704234,0.00046553146,0.007853103,0.0004012893,0.00046135965,0.15882343,0.0030208544,0.006070618,0.78212416],"study_design_scores_gemma":[0.0015691103,0.018853137,0.17929973,0.0014916942,0.0017134184,0.09161043,0.00062937546,0.001461606,0.25641525,0.0020246317,0.44484785,0.00008379269],"about_ca_topic_score_codex":0.000932868,"about_ca_topic_score_gemma":0.0014631016,"teacher_disagreement_score":0.0025556316,"about_ca_system_score_codex":0.00042659827,"about_ca_system_score_gemma":0.00028537316,"threshold_uncertainty_score":0.008549452},"labels":[],"label_agreement":null},{"id":"W2009690780","doi":"10.2165/00063030-200418020-00001","title":"Business Ethics 101 for the Biotech Industry","year":2004,"lang":"en","type":"review","venue":"BioDrugs","topic":"Biotechnology and Related Fields","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint Mary's University","funders":"","keywords":"Drug industry; Business ethics; Business; Management; Biotechnology; Engineering ethics; Medicine; Biology; Engineering; Economics","score_opus":0.12002475341069896,"score_gpt":0.3866064633007289,"score_spread":0.26658170989002994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009690780","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020120392,0.9473218,0.00064673566,0.022998687,0.00247429,0.000025085106,0.000018381032,0.000015292655,0.026298542],"genre_scores_gemma":[0.0076151416,0.90741813,0.0021667983,0.051626638,0.0023466826,0.00012411286,0.00006542709,0.000019356965,0.028617756],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961708,0.0017401456,0.00023276896,0.00021972814,0.0014302859,0.00020624034],"domain_scores_gemma":[0.9958877,0.0025484278,0.00033219464,0.0001484236,0.00093593035,0.00014728458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004775179,0.0010730425,0.0015576369,0.0024983361,0.001212208,0.0039731227,0.0012035421,0.009182724,0.0039866585],"category_scores_gemma":[0.008352148,0.00043154493,0.00068328384,0.0027990472,0.0029869725,0.0028982826,0.0013318717,0.0053002657,0.002016785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005130685,0.00007602188,0.00021435201,0.0065000546,0.00006979541,0.0007533783,0.00032108248,0.0004955553,0.00072466064,0.11918109,0.35664454,0.51496816],"study_design_scores_gemma":[0.00001286314,0.00001720968,0.0002889382,0.0039010954,0.000021303593,0.00044318853,0.00008307329,0.00004091068,0.00009159735,0.0108725075,0.9842195,0.000007741447],"about_ca_topic_score_codex":0.0060706763,"about_ca_topic_score_gemma":0.011469441,"teacher_disagreement_score":0.009182724,"about_ca_system_score_codex":0.004533234,"about_ca_system_score_gemma":0.01106869,"threshold_uncertainty_score":0.032891035},"labels":[],"label_agreement":null},{"id":"W2012092068","doi":"10.2165/00063030-200317001-00006","title":"Current Status and Replies to Frequently Posed Questions on Atovaquone Plus Proguanil (Malarone??) for the Prevention of Malaria","year":2003,"lang":"en","type":"review","venue":"BioDrugs","topic":"Malaria Research and Control","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Proguanil; Malaria; Atovaquone; Mefloquine; Medicine; Chloroquine; Chemoprophylaxis; Malaria prophylaxis; Artemisinin; Intensive care medicine; Primaquine; Plasmodium falciparum; Pharmacology; Immunology; Internal medicine","score_opus":0.07494769191811303,"score_gpt":0.39599828050135083,"score_spread":0.3210505885832378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012092068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013050574,0.99643624,0.000044822264,0.0020007577,0.00055075885,0.0000063524335,0.000048640093,0.0000034696543,0.00077843975],"genre_scores_gemma":[0.00066295435,0.9970336,0.00012140162,0.0010850137,0.00043077552,0.00001004251,0.000058667374,0.0000015430473,0.00059603585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99946386,0.00013395364,0.0001396964,0.00006117983,0.00016570953,0.000035687994],"domain_scores_gemma":[0.9960334,0.002705803,0.00057773275,0.000032818574,0.00055688526,0.0000933186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024032348,0.00061168853,0.002323283,0.0022992888,0.00033876137,0.001744609,0.0009497599,0.0021088477,0.006684823],"category_scores_gemma":[0.006020713,0.00039647275,0.0009135085,0.00413136,0.0005547659,0.002034542,0.0007136246,0.001705582,0.002281393],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034312066,0.00004045362,0.00028753356,0.041148152,0.00016569381,0.00019903347,0.00017475254,0.00018775622,0.000824928,0.0013955326,0.06764306,0.88758993],"study_design_scores_gemma":[0.00007878758,0.00018249697,0.0012076505,0.019760378,0.0006069336,0.0007932226,0.000324621,0.00007408428,0.00040493085,0.00090939825,0.9756267,0.0000307312],"about_ca_topic_score_codex":0.0021771786,"about_ca_topic_score_gemma":0.005287946,"teacher_disagreement_score":0.006684823,"about_ca_system_score_codex":0.0008348858,"about_ca_system_score_gemma":0.0017913193,"threshold_uncertainty_score":0.022362888},"labels":[],"label_agreement":null},{"id":"W2015187915","doi":"10.2165/00063030-200822040-00002","title":"Strategies Toward the Improved Oral Delivery of Insulin Nanoparticles via Gastrointestinal Uptake and Translocation","year":2008,"lang":"en","type":"review","venue":"BioDrugs","topic":"Advanced Drug Delivery Systems","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Insulin; Glycemic; Gastrointestinal tract; Nanoparticle; Diabetes mellitus; Nanotechnology; Pharmacology; Medicine; Chemistry; Materials science; Internal medicine; Endocrinology","score_opus":0.15896326056502963,"score_gpt":0.4157631336086455,"score_spread":0.25679987304361584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015187915","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004744276,0.9808414,0.009544963,0.0005456135,0.00029220525,0.00004498123,0.000036826612,0.00006882945,0.0038808251],"genre_scores_gemma":[0.013354684,0.97384316,0.006870451,0.00037078874,0.0001425109,0.00006191965,0.000082166196,0.000012465569,0.005261956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998909,0.000015551692,0.00000945569,0.000024548237,0.000042013045,0.00001762389],"domain_scores_gemma":[0.99993575,0.00002133624,0.0000149795,0.0000039445426,0.000017977096,0.000005965933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044525767,0.0010035895,0.0013003468,0.0010427535,0.00020409435,0.0008675411,0.0008170962,0.0010389022,0.0013101564],"category_scores_gemma":[0.00018566161,0.0003477875,0.00047463595,0.0008659583,0.0005061766,0.001107214,0.000645596,0.0015652045,0.00135857],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013853065,0.0003059311,0.0001263914,0.008024455,0.00006681608,0.00051676214,0.000114234455,0.0013158987,0.12951311,0.009964131,0.006193011,0.8437208],"study_design_scores_gemma":[0.0001016861,0.0006903361,0.00089702546,0.0011234998,0.0001692161,0.0028878513,0.00010014599,0.0017974735,0.121531636,0.0042504305,0.8663791,0.00007160989],"about_ca_topic_score_codex":0.0007260182,"about_ca_topic_score_gemma":0.0009816417,"teacher_disagreement_score":0.0013101564,"about_ca_system_score_codex":0.0006817069,"about_ca_system_score_gemma":0.0004329634,"threshold_uncertainty_score":0.0049461722},"labels":[],"label_agreement":null},{"id":"W2016399234","doi":"10.2165/00063030-200923010-00002","title":"MicroRNA-Based Therapeutics for Cancer","year":2009,"lang":"en","type":"review","venue":"BioDrugs","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":159,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"microRNA; Biology; Translation (biology); Oncomir; Cancer; Signal transduction; Computational biology; Cancer research; Bioinformatics; Gene; Messenger RNA; Cell biology; Genetics","score_opus":0.048097010165034176,"score_gpt":0.3556908438159273,"score_spread":0.3075938336508931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016399234","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035882776,0.99175984,0.00234714,0.00055556296,0.0011565745,0.000023361117,0.000032406457,0.000042783788,0.00372351],"genre_scores_gemma":[0.0034698048,0.98832977,0.0024038178,0.00072365545,0.0006505096,0.000061095125,0.00009127158,0.000011572205,0.004258496],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997751,0.000042824588,0.00002425425,0.00004246673,0.00008914777,0.000026088821],"domain_scores_gemma":[0.9997873,0.000111661386,0.000027196616,0.000010147816,0.00003979405,0.000024010316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000977343,0.0014743593,0.0018789279,0.001574047,0.00038911946,0.0008320446,0.001094789,0.0016792549,0.0038250957],"category_scores_gemma":[0.0008093802,0.00048512465,0.00055129087,0.0014251976,0.00090277655,0.0013477383,0.00090608426,0.0030897742,0.0029663213],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015627083,0.00016166606,0.00008917292,0.003962094,0.00008399452,0.00033791928,0.00004530888,0.00077006436,0.010803558,0.010145403,0.047422796,0.92602175],"study_design_scores_gemma":[0.00007410044,0.00016330238,0.00026138537,0.00058091595,0.00008871453,0.0010747376,0.000025536801,0.0004308949,0.003785917,0.0039541707,0.989537,0.00002331296],"about_ca_topic_score_codex":0.0005401884,"about_ca_topic_score_gemma":0.0016807185,"teacher_disagreement_score":0.0038250957,"about_ca_system_score_codex":0.000818424,"about_ca_system_score_gemma":0.0006573256,"threshold_uncertainty_score":0.012796223},"labels":[],"label_agreement":null},{"id":"W2024217378","doi":"10.2165/00063030-200014020-00006","title":"Photodynamic Therapy in Immune (Non-Oncological) Disorders","year":2000,"lang":"en","type":"article","venue":"BioDrugs","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; QLT (Canada)","funders":"","keywords":"Photodynamic therapy; Verteporfin; Medicine; Immune system; Cancer research; Immunology; Chemistry; Surgery","score_opus":0.011536345573356716,"score_gpt":0.30031890629598984,"score_spread":0.28878256072263314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024217378","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72555757,0.24672705,0.0028118822,0.0014551766,0.0002987536,0.0002072736,0.00009810221,0.00003251144,0.022811674],"genre_scores_gemma":[0.9061249,0.08010144,0.002798956,0.00056375866,0.00023668366,0.00017816715,0.00012424735,0.000011896588,0.009859944],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979657,0.00009734596,0.000016172668,0.0000218261,0.000022456674,0.000045693236],"domain_scores_gemma":[0.99980706,0.00011029639,0.000027490625,0.000023185683,0.00001634325,0.00001565365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011002608,0.00026795323,0.00029203892,0.0006665753,0.00036281534,0.00043338293,0.00027671744,0.0005917185,0.0027462428],"category_scores_gemma":[0.00045117535,0.0000908866,0.00025970538,0.0004234956,0.0005891504,0.0006542534,0.00030334076,0.00046926783,0.00033655486],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008267261,0.0063419337,0.005962791,0.0032407187,0.00015598781,0.002721593,0.0010961406,0.000649344,0.63403624,0.03492341,0.0034633116,0.29914132],"study_design_scores_gemma":[0.0012211466,0.019899482,0.020107364,0.0005382712,0.00037219358,0.010704735,0.0011087746,0.00065169716,0.8190947,0.006862513,0.11940743,0.000031738866],"about_ca_topic_score_codex":0.00053667347,"about_ca_topic_score_gemma":0.0004643215,"teacher_disagreement_score":0.0027462428,"about_ca_system_score_codex":0.00041836954,"about_ca_system_score_gemma":0.00037412933,"threshold_uncertainty_score":0.009187162},"labels":[],"label_agreement":null},{"id":"W2029930411","doi":"10.1007/s40259-014-0099-9","title":"Similar Names for Similar Biologics","year":2014,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Amicus Therapeutics; Amgen","keywords":"Biosimilar; Pharmacovigilance; Interchangeability; Medicine; Product (mathematics); Pharmacology; Computer science; Adverse effect","score_opus":0.022341485618954108,"score_gpt":0.2784489941231749,"score_spread":0.2561075085042208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029930411","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01799577,0.07057581,0.1724901,0.021130402,0.14761367,0.0008258478,0.005078983,0.0044199503,0.5598694],"genre_scores_gemma":[0.14247441,0.060622714,0.19736971,0.031775746,0.023577673,0.0012944534,0.011616238,0.0033047039,0.52796435],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99789715,0.0006203998,0.0003116405,0.0004081961,0.00045131423,0.0003112909],"domain_scores_gemma":[0.9958389,0.0013853661,0.000781982,0.0007532776,0.0008566261,0.00038394742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014328108,0.001468189,0.0011097832,0.0032486923,0.0020509085,0.0035375752,0.0014269421,0.0024469623,0.04847387],"category_scores_gemma":[0.0048508346,0.00034441866,0.001424766,0.0049568866,0.003952804,0.005363673,0.0024921836,0.0049626264,0.033593345],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003569894,0.00011142128,0.0005053623,0.0018970604,0.00009114343,0.0010880072,0.0008381646,0.00034699435,0.011234726,0.50524884,0.27839145,0.19988981],"study_design_scores_gemma":[0.000010288975,0.000041984644,0.00016055007,0.00009214657,0.000014637885,0.0007415085,0.00010237858,0.000099036144,0.0011062678,0.012549287,0.98506886,0.000013103296],"about_ca_topic_score_codex":0.00061717536,"about_ca_topic_score_gemma":0.0009706504,"teacher_disagreement_score":0.04847387,"about_ca_system_score_codex":0.0012147115,"about_ca_system_score_gemma":0.0015661959,"threshold_uncertainty_score":0.16216123},"labels":[],"label_agreement":null},{"id":"W2030438860","doi":"10.2165/11206830-000000000-00000","title":"Spotlight on AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®)†","year":2011,"lang":"en","type":"article","venue":"BioDrugs","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Immunogenicity; Medicine; Cervical cancer; Virology; Adjuvant; Immunology; Cervical intraepithelial neoplasia; HPV vaccines; DNA vaccination; Immune system; Vaccination; HPV infection; Immunization; Cancer; Internal medicine","score_opus":0.08524794751241882,"score_gpt":0.3382199901668697,"score_spread":0.2529720426544509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030438860","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02918601,0.58787304,0.008649261,0.2239234,0.078093596,0.00050967775,0.002171677,0.00068010873,0.06891325],"genre_scores_gemma":[0.103014976,0.47804782,0.0114750285,0.16302383,0.048521716,0.00062203046,0.002921318,0.0002705457,0.19210275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993493,0.00014070144,0.000050899915,0.000102992,0.00021117114,0.00014496372],"domain_scores_gemma":[0.9984505,0.0004940181,0.00012257467,0.000035722594,0.00060874445,0.0002883964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022959185,0.00065724074,0.0008621784,0.0005286842,0.0005243581,0.0013621905,0.00080620346,0.004209957,0.019934727],"category_scores_gemma":[0.0016618099,0.0002995458,0.0006252069,0.00051440956,0.00068143633,0.0015592292,0.00061893696,0.0029014947,0.004906267],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027759816,0.00042161703,0.00049528526,0.002568046,0.000052409676,0.00039220424,0.00008014402,0.00048732324,0.041229546,0.007727487,0.4214121,0.5223579],"study_design_scores_gemma":[0.00031470036,0.0025248416,0.0010151941,0.00054378534,0.000086048574,0.00049821305,0.0001151097,0.0005240519,0.013777433,0.003049525,0.9775163,0.00003470416],"about_ca_topic_score_codex":0.0016208497,"about_ca_topic_score_gemma":0.002957547,"teacher_disagreement_score":0.019934727,"about_ca_system_score_codex":0.0008651262,"about_ca_system_score_gemma":0.0019491712,"threshold_uncertainty_score":0.06668824},"labels":[],"label_agreement":null},{"id":"W2047330433","doi":"10.2165/00063030-200923020-00002","title":"Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy","year":2009,"lang":"en","type":"review","venue":"BioDrugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; McGill University Health Centre","funders":"Howard Hughes Medical Institute","keywords":"PI3K/AKT/mTOR pathway; Sirolimus; Protein kinase B; Cancer; Cancer research; RPTOR; Signal transduction; Pharmacology; Biology; Medicine; Internal medicine; Cell biology","score_opus":0.07859009767915429,"score_gpt":0.35351198432365355,"score_spread":0.27492188664449924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047330433","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015861484,0.9969542,0.0004425022,0.0007544792,0.00034550662,0.000006032711,0.000015097067,0.000013655658,0.0013099478],"genre_scores_gemma":[0.0009766784,0.9963391,0.00071737217,0.0004613789,0.00040269957,0.000014878082,0.000029258052,0.0000039091474,0.0010548148],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997397,0.000048133774,0.00003314451,0.000046807003,0.000100336525,0.000031826377],"domain_scores_gemma":[0.99951994,0.00027879377,0.000047541183,0.000014631284,0.00010338722,0.000035683184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015847982,0.00097414217,0.0020239884,0.0014469085,0.00045345645,0.0016006503,0.0013789173,0.001986697,0.0048265005],"category_scores_gemma":[0.0012501011,0.0004798474,0.00058166485,0.001725396,0.00095826987,0.0024205165,0.0008693256,0.0029411763,0.0029577268],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020030684,0.0001427214,0.00015378371,0.0075217467,0.00007104837,0.000290652,0.000045020344,0.0008146835,0.0037906722,0.0075710667,0.042902134,0.93649626],"study_design_scores_gemma":[0.000057264788,0.00015906629,0.00032893202,0.0013473548,0.000115033385,0.0010865119,0.00005537087,0.0003478176,0.0014150616,0.003193328,0.9918732,0.000021047703],"about_ca_topic_score_codex":0.0011783099,"about_ca_topic_score_gemma":0.0030394082,"teacher_disagreement_score":0.0048265005,"about_ca_system_score_codex":0.00092689553,"about_ca_system_score_gemma":0.0012702491,"threshold_uncertainty_score":0.016146183},"labels":[],"label_agreement":null},{"id":"W204758488","doi":"10.2165/00063030-200721010-00002","title":"Therapeutic and Prophylactic Potential of Small Interfering RNAs against Severe Acute Respiratory Syndrome","year":2007,"lang":"en","type":"review","venue":"BioDrugs","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto; University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Small interfering RNA; RNA interference; Virology; RNA; Biology; Medicine; Coronavirus; Immunology; Coronavirus disease 2019 (COVID-19); Gene; Infectious disease (medical specialty); Pathology; Disease","score_opus":0.0431896343897843,"score_gpt":0.3051160456634367,"score_spread":0.2619264112736524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W204758488","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00074666104,0.99521834,0.0011884809,0.00032832037,0.00031391892,0.000013070242,0.000020255558,0.000024967925,0.0021459383],"genre_scores_gemma":[0.004484117,0.99107844,0.0014877343,0.0003720613,0.0002895398,0.00003344323,0.000067629895,0.0000049282307,0.0021821093],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998723,0.000019916934,0.0000141833525,0.000019351563,0.000057587386,0.000016594438],"domain_scores_gemma":[0.9998574,0.000078143465,0.00002068267,0.0000049140076,0.000028141227,0.000010591475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050249783,0.00086516165,0.0013028515,0.001039883,0.00022344342,0.0006146037,0.00087759126,0.0012049467,0.0019175857],"category_scores_gemma":[0.00036491692,0.00022282028,0.0003365632,0.00086363376,0.0005002133,0.0006345157,0.00035438704,0.0014798541,0.0011839117],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015557092,0.000121965284,0.00011627934,0.0037551776,0.00004796171,0.0004114497,0.000036054586,0.00060754304,0.014712221,0.0042258385,0.011014547,0.9647955],"study_design_scores_gemma":[0.00010475811,0.00037460693,0.0009930182,0.0010072336,0.00014196242,0.0035623428,0.000042481915,0.0004324612,0.010088733,0.0027848836,0.9804348,0.00003282388],"about_ca_topic_score_codex":0.00046595332,"about_ca_topic_score_gemma":0.00082523434,"teacher_disagreement_score":0.0019175857,"about_ca_system_score_codex":0.0004260602,"about_ca_system_score_gemma":0.00046305053,"threshold_uncertainty_score":0.0064148903},"labels":[],"label_agreement":null},{"id":"W2052842550","doi":"10.2165/00063030-200115120-00005","title":"Current and Future Applications of Immunological Attenuation via Pegylation of Cells and Tissue","year":2001,"lang":"en","type":"review","venue":"BioDrugs","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Transplantation; PEGylation; Immune system; Immunology; Immunosuppression; Immunogenicity; Immunologic Tolerance; Antigenicity; Alloimmunity; Antibody; Medicine; In vivo; Immune tolerance; Cancer research; Biology; Internal medicine","score_opus":0.029765588536721496,"score_gpt":0.32197767037472635,"score_spread":0.29221208183800484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052842550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019569905,0.98827875,0.003976816,0.00054274674,0.00039952213,0.000016617221,0.000018231589,0.000031987733,0.004778347],"genre_scores_gemma":[0.0063240738,0.98544145,0.0029372394,0.0005342187,0.00027332388,0.0000273488,0.00006185724,0.000006927361,0.0043935087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998963,0.000015603535,0.000012896835,0.00002485167,0.000034006094,0.00001637432],"domain_scores_gemma":[0.9998492,0.00007565676,0.000022589056,0.000008910851,0.00002868366,0.000014833576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008282859,0.00086161506,0.00090352213,0.00074993045,0.00024135978,0.0008015255,0.00085021404,0.0012057574,0.0030383754],"category_scores_gemma":[0.00032241928,0.00023455343,0.00040378072,0.00082879397,0.0005628518,0.0018031921,0.0003529014,0.0011811097,0.0015677416],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023429634,0.00023568312,0.00022358591,0.00424351,0.000038986953,0.0003714926,0.00006791837,0.00081289234,0.03941817,0.0064007025,0.006099342,0.9418533],"study_design_scores_gemma":[0.000085066764,0.00060685544,0.0011770182,0.0010070944,0.0001387355,0.0031793313,0.00012072784,0.0006248199,0.029158592,0.00488332,0.95898247,0.00003596129],"about_ca_topic_score_codex":0.0004720807,"about_ca_topic_score_gemma":0.0008659447,"teacher_disagreement_score":0.0030383754,"about_ca_system_score_codex":0.0004628841,"about_ca_system_score_gemma":0.00051293144,"threshold_uncertainty_score":0.01016438},"labels":[],"label_agreement":null},{"id":"W2061784015","doi":"10.2165/11539070-000000000-00000","title":"Systemic and Mucosal Delivery of Drugs within Polymeric Microparticles Produced by Spray Drying","year":2010,"lang":"en","type":"review","venue":"BioDrugs","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Spray drying; Drug delivery; Controlled release; Drug; Dosage form; Chitosan; Pharmacology; Nanotechnology; Materials science; Chemistry; Medicine; Chromatography; Organic chemistry","score_opus":0.020817535020426242,"score_gpt":0.29111167183393394,"score_spread":0.27029413681350767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061784015","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006617314,0.9874724,0.0026190728,0.000085398315,0.00012855491,0.000026355794,0.000030063944,0.00003952626,0.0029813123],"genre_scores_gemma":[0.021313785,0.96729994,0.0031619307,0.00014598425,0.00013778657,0.000033029788,0.000091334565,0.000012148722,0.0078041805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99991274,0.0000081486005,0.000008913806,0.000020593941,0.000038072318,0.00001150862],"domain_scores_gemma":[0.99995184,0.000017624376,0.0000129969,0.0000026413768,0.0000114498325,0.0000035111898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002816106,0.00072622485,0.00092910737,0.0011263454,0.00013328942,0.0003952655,0.00042902236,0.0005740052,0.00087856967],"category_scores_gemma":[0.00013818027,0.00026598645,0.0003351593,0.0008441769,0.00025543492,0.000616809,0.00027287248,0.0006297895,0.00084791676],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014064848,0.00015124216,0.00011387206,0.0077730017,0.000059763577,0.00039457998,0.00006384799,0.0005673835,0.20555949,0.0016222597,0.003308829,0.78024507],"study_design_scores_gemma":[0.00006189488,0.00094681466,0.0027209413,0.0011513688,0.0002694234,0.0051785046,0.00007727628,0.0010800385,0.25693488,0.00095657096,0.7305489,0.000073457144],"about_ca_topic_score_codex":0.000518577,"about_ca_topic_score_gemma":0.00078668963,"teacher_disagreement_score":0.0011263454,"about_ca_system_score_codex":0.0003015622,"about_ca_system_score_gemma":0.0002245679,"threshold_uncertainty_score":0.002939105},"labels":[],"label_agreement":null},{"id":"W2067292160","doi":"10.2165/11586210-000000000-00000","title":"Autoimmune Hepatitis Induced by Infliximab in a Patient with Crohnʼs Disease with no Relapse After Switching to Adalimumab","year":2010,"lang":"en","type":"article","venue":"BioDrugs","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alberta Innovates - Health Solutions","keywords":"Infliximab; Adalimumab; Medicine; Autoimmune hepatitis; Crohn's disease; Internal medicine; Disease; Gastroenterology; Inflammatory bowel disease; Tumor necrosis factor alpha; Hepatitis; Immunology","score_opus":0.004201924402870781,"score_gpt":0.2110650540486236,"score_spread":0.20686312964575282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067292160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816443,0.0016152326,0.0005793648,0.0037625525,0.00038577052,0.00008691827,0.00014359881,0.00010468818,0.011677497],"genre_scores_gemma":[0.9966066,0.00037648063,0.00020975017,0.0011978116,0.00049897446,0.000010015508,0.00010021877,0.000017139753,0.0009830459],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99944574,0.00008358265,0.00007639132,0.0001188714,0.000057716734,0.00021770457],"domain_scores_gemma":[0.9984084,0.0005155272,0.00020551599,0.00015604905,0.0000985565,0.0006159494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039299706,0.0012867673,0.0012124856,0.0017745849,0.0021393,0.0011745167,0.0012181521,0.00466136,0.0031750437],"category_scores_gemma":[0.0028381892,0.0007050665,0.002150501,0.00090609724,0.0010919939,0.0010400747,0.0007313427,0.0037283057,0.0009826889],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049545814,0.00017737276,0.019668097,0.000028486229,0.000030867417,0.9764854,0.00018502162,0.00006011752,0.0008551185,0.000074733456,0.00026836843,0.0016709907],"study_design_scores_gemma":[0.00019334303,0.001010188,0.048238333,0.000029502764,0.000121417506,0.94791573,0.00025336997,0.0005550026,0.00073641096,0.00014425495,0.0007658762,0.00003655049],"about_ca_topic_score_codex":0.0034408842,"about_ca_topic_score_gemma":0.0032204709,"teacher_disagreement_score":0.00466136,"about_ca_system_score_codex":0.0012410969,"about_ca_system_score_gemma":0.00073469925,"threshold_uncertainty_score":0.010621607},"labels":[],"label_agreement":null},{"id":"W2073194177","doi":"10.2165/00063030-200620010-00001","title":"The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases","year":2006,"lang":"en","type":"review","venue":"BioDrugs","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; University of Alberta","funders":"National Heart, Lung, and Blood Institute","keywords":"Oligonucleotide; Genetic enhancement; Small interfering RNA; RNA interference; RNA; Immune system; Biology; Translation (biology); Medicine; Pharmacology; Messenger RNA; Computational biology; Gene; Immunology; Genetics","score_opus":0.023349191964029858,"score_gpt":0.3058975377542738,"score_spread":0.28254834579024396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073194177","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019525694,0.9967398,0.0009684993,0.00057067367,0.0004551654,0.000006546844,0.000010523869,0.000018979274,0.0010345324],"genre_scores_gemma":[0.0012122812,0.9957628,0.001051881,0.00039533773,0.0003546973,0.000015056006,0.000023483812,0.0000030213698,0.0011813234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978524,0.00004406715,0.000022162623,0.000033127628,0.00009054651,0.000024861449],"domain_scores_gemma":[0.9997191,0.00014260564,0.000035426063,0.0000076209644,0.00006421748,0.00003100785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011526643,0.0011458434,0.0017948099,0.0013892303,0.00036326182,0.0011086568,0.0014611448,0.0020878103,0.0034079058],"category_scores_gemma":[0.0005581963,0.0003539616,0.0004757763,0.0013809556,0.0009184713,0.0021573594,0.0005981786,0.0027391007,0.0023610855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023062472,0.00015527153,0.000118000266,0.0065039657,0.0000702371,0.00043026544,0.000074133175,0.0009782361,0.012768635,0.009931551,0.027885033,0.94085395],"study_design_scores_gemma":[0.00008277588,0.00024877695,0.00034353914,0.00090475555,0.00007975882,0.0014499156,0.000055076714,0.00038674002,0.002196403,0.004351832,0.9898733,0.000027079619],"about_ca_topic_score_codex":0.0009622602,"about_ca_topic_score_gemma":0.0023051593,"teacher_disagreement_score":0.0034079058,"about_ca_system_score_codex":0.00084242795,"about_ca_system_score_gemma":0.0009154084,"threshold_uncertainty_score":0.011400521},"labels":[],"label_agreement":null},{"id":"W2079402257","doi":"10.2165/00063030-200115050-00001","title":"C2 Monitoring Strategy for Optimising Cyclosporin Immunosuppression from the Neoral??* Formulation","year":2001,"lang":"en","type":"review","venue":"BioDrugs","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Immunosuppression; Medicine; Therapeutic drug monitoring; Nephrotoxicity; Trough level; Transplantation; Kidney transplantation; Urology; Ciclosporin; Pharmacology; Internal medicine; Drug; Kidney; Tacrolimus","score_opus":0.2002765864096752,"score_gpt":0.4437927799303807,"score_spread":0.2435161935207055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079402257","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034957934,0.9241226,0.012738637,0.0011568359,0.0007156786,0.00029850015,0.0003218633,0.00016452737,0.025523402],"genre_scores_gemma":[0.18188058,0.7695251,0.018303214,0.0017464219,0.00044854693,0.00031504247,0.000686446,0.000044180408,0.027050512],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999132,0.00002030536,0.000008299984,0.000016408552,0.00003100973,0.000010715879],"domain_scores_gemma":[0.9999362,0.00001657522,0.00002035395,0.0000037975212,0.00001823836,0.000004786948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031102655,0.00045571057,0.00045568257,0.0005498653,0.00015285869,0.0004531339,0.0005162184,0.00053339713,0.0023627654],"category_scores_gemma":[0.00019834981,0.00009106218,0.00019849358,0.00048432758,0.00018842376,0.00040584066,0.00019036104,0.0004995967,0.0007899104],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006811445,0.00022304578,0.00024563505,0.00472323,0.000036520174,0.000354514,0.00002929356,0.0008330742,0.09413755,0.0029227692,0.006162378,0.8896509],"study_design_scores_gemma":[0.00025811265,0.0019041771,0.0021971276,0.0010552871,0.00024201187,0.0037930314,0.00006884924,0.0016231732,0.30551925,0.0011993208,0.6820982,0.000041426098],"about_ca_topic_score_codex":0.0012230449,"about_ca_topic_score_gemma":0.001302516,"teacher_disagreement_score":0.0023627654,"about_ca_system_score_codex":0.00048630036,"about_ca_system_score_gemma":0.0005306673,"threshold_uncertainty_score":0.007904232},"labels":[],"label_agreement":null},{"id":"W2089502375","doi":"10.1007/s40259-012-0003-4","title":"Targeting Focal Adhesion Kinase in Fibrotic Diseases","year":2012,"lang":"en","type":"review","venue":"BioDrugs","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Fibrosis; Extracellular matrix; Focal adhesion; Medicine; Scleroderma (fungus); Pulmonary fibrosis; Idiopathic pulmonary fibrosis; Cancer research; Signal transduction; Pathology; Immunology; Biology; Lung; Cell biology; Internal medicine","score_opus":0.03822410845400634,"score_gpt":0.3191907090961403,"score_spread":0.28096660064213397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089502375","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029148295,0.9974795,0.00038023505,0.00019964573,0.00020573364,0.00001335086,0.000028076602,0.000013199962,0.0013888326],"genre_scores_gemma":[0.0015410865,0.9961649,0.000444189,0.00026692433,0.00015644872,0.000018562425,0.000053667096,0.0000025327306,0.0013517453],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987566,0.000018396724,0.00002038125,0.000020536538,0.000047091256,0.000017906788],"domain_scores_gemma":[0.9998217,0.000083068146,0.00003474678,0.0000053667027,0.00003708807,0.000018017987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055191206,0.0011701204,0.0017493331,0.0019973295,0.00020182286,0.0008136771,0.00067421043,0.0012041384,0.0032003787],"category_scores_gemma":[0.00057427795,0.0003994617,0.0005290103,0.0014246663,0.00042182472,0.0012752637,0.0006147956,0.001876573,0.0017031197],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017871297,0.0001558532,0.000097331686,0.01518318,0.00011231488,0.00023026096,0.000044028882,0.0006306579,0.0070453105,0.0022404753,0.024238816,0.94984305],"study_design_scores_gemma":[0.00014351816,0.0003562249,0.0008265689,0.003381181,0.00038832592,0.0017019182,0.00004949545,0.0004317521,0.0028884406,0.0015496697,0.98824674,0.000036165708],"about_ca_topic_score_codex":0.00071941403,"about_ca_topic_score_gemma":0.0016497737,"teacher_disagreement_score":0.0032003787,"about_ca_system_score_codex":0.00041778886,"about_ca_system_score_gemma":0.0006237371,"threshold_uncertainty_score":0.010706365},"labels":[],"label_agreement":null},{"id":"W2131592861","doi":"10.1007/s40259-015-0130-9","title":"Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib","year":2015,"lang":"en","type":"review","venue":"BioDrugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Boehringer Ingelheim","keywords":"Afatinib; Erlotinib; Gefitinib; Epidermal growth factor receptor; Lung cancer; Medicine; Oncology; Cetuximab; Internal medicine; EGFR inhibitors; Cancer research; Tyrosine kinase; Pharmacology; Cancer; Receptor","score_opus":0.1326961338418439,"score_gpt":0.3950047831603708,"score_spread":0.26230864931852693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131592861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016494817,0.9935921,0.0011926469,0.00090745295,0.00044667846,0.000016305941,0.000027477192,0.000022586715,0.0021451968],"genre_scores_gemma":[0.013482001,0.9805705,0.0012839194,0.001247476,0.000728535,0.00002411784,0.00007872494,0.000008856733,0.002575847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998435,0.00003256673,0.000021155047,0.000035372163,0.00004313095,0.00002427544],"domain_scores_gemma":[0.99989486,0.000043921766,0.000018639852,0.0000032831997,0.000025050847,0.000014303793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043342568,0.00045867235,0.00063378224,0.0006099479,0.00012433165,0.00050629635,0.00045552797,0.0007161631,0.0010248731],"category_scores_gemma":[0.00032775206,0.00017348955,0.00044444983,0.000617607,0.00024091813,0.0011844526,0.0003567997,0.0013637891,0.00066519657],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020940007,0.00017744777,0.0004720154,0.009799383,0.00014256261,0.0008242025,0.00013613103,0.0014011521,0.0191651,0.009133227,0.032734826,0.9258045],"study_design_scores_gemma":[0.00007010647,0.00081852084,0.0011748001,0.00091907685,0.0001668851,0.00498335,0.000061837185,0.0007723478,0.00528434,0.0022386198,0.9834803,0.000029963054],"about_ca_topic_score_codex":0.0003430118,"about_ca_topic_score_gemma":0.0009490711,"teacher_disagreement_score":0.0010248731,"about_ca_system_score_codex":0.0004492086,"about_ca_system_score_gemma":0.0003365645,"threshold_uncertainty_score":0.0034285188},"labels":[],"label_agreement":null},{"id":"W217783584","doi":"10.1007/s40259-015-0126-5","title":"Status and Prospects of Aptamers as Drug Components","year":2015,"lang":"en","type":"review","venue":"BioDrugs","topic":"Advanced biosensing and bioanalysis techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"","keywords":"Aptamer; Drug; Pharmacotherapy; Medicine; Computational biology; Intensive care medicine; Pharmacology; Biology; Internal medicine; Genetics","score_opus":0.02908022629780935,"score_gpt":0.335241854693982,"score_spread":0.3061616283961726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W217783584","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029889226,0.9978573,0.00045512302,0.00016343479,0.00012749464,0.0000037567295,0.000012677016,0.0000067426786,0.0010745449],"genre_scores_gemma":[0.0020090174,0.9956785,0.00064673746,0.00025072537,0.00018570435,0.0000086799855,0.000028052486,0.0000025306972,0.0011900531],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997757,0.000035434354,0.000024651912,0.000051707255,0.000080944905,0.000031591288],"domain_scores_gemma":[0.9996934,0.00016990471,0.000048156748,0.000012748324,0.000051126768,0.000024740084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007594556,0.00088584295,0.0010875158,0.0015147474,0.00021322354,0.0013043706,0.000923675,0.0013568385,0.0030588503],"category_scores_gemma":[0.0007364229,0.0003975669,0.0004541581,0.0016524846,0.0006723086,0.0018983091,0.00097496115,0.0015368303,0.0019002064],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009534609,0.00009992984,0.00023216866,0.009581142,0.000050121052,0.00021143733,0.00006963771,0.0006597606,0.011106626,0.009535737,0.010670484,0.95768774],"study_design_scores_gemma":[0.000016495378,0.0001392623,0.00044748487,0.0011533842,0.00007739222,0.00092272455,0.00005049969,0.0003071009,0.004274088,0.0036818911,0.9889059,0.000023773742],"about_ca_topic_score_codex":0.00050540816,"about_ca_topic_score_gemma":0.0007939542,"teacher_disagreement_score":0.0030588503,"about_ca_system_score_codex":0.0004665286,"about_ca_system_score_gemma":0.00067295926,"threshold_uncertainty_score":0.010232866},"labels":[],"label_agreement":null},{"id":"W2277879584","doi":"10.1007/s40259-016-0162-9","title":"Trastuzumab in the Treatment of Breast Cancer","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Norwegian Institute of Public Health; Direktorat Jenderal Pendidikan Tinggi; Sanofi Pasteur; Johns Hopkins Bloomberg School of Public Health; University of Illinois at Urbana-Champaign; National Institutes of Health; Seqirus; Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja; Ministero della Salute; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; Bundesministerium für Bildung und Forschung; Novavax; Sanofi; Comunidad de Madrid; Boston Scientific Corporation; Public Health England; University of Calgary; Arizona State University; GlaxoSmithKline; Bristol-Myers Squibb; Australian Government; Pfizer; Lembaga Pengelola Dana Pendidikan; Johns Hopkins University; Edwards Lifesciences; Bill and Melinda Gates Foundation; Instituto de Salud Carlos III; Amgen; Damon Runyon Cancer Research Foundation; Medical Research Council; Teva Pharmaceutical Industries; South African Medical Research Council; Seoul National University; U.S. Department of Veterans Affairs; Genentech; U.S. Environmental Protection Agency","keywords":"Trastuzumab; Pertuzumab; Medicine; Lapatinib; Breast cancer; Cardiotoxicity; Cancer; Disease; Oncology; Targeted therapy; Internal medicine; Pharmacology; Chemotherapy","score_opus":0.13866766770733222,"score_gpt":0.47618576035695515,"score_spread":0.33751809264962296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277879584","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005737072,0.9993703,0.000038928036,0.00010909416,0.000086028915,0.0000026668502,0.000009374323,0.0000025104064,0.0003237922],"genre_scores_gemma":[0.0004396165,0.99898905,0.000062557105,0.00013428589,0.00008559346,0.0000027385622,0.00001608973,6.65057e-7,0.00026936532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997869,0.000043553242,0.000035773002,0.00003232361,0.00007680229,0.000024766761],"domain_scores_gemma":[0.9996655,0.00018193378,0.000058887854,0.000007706467,0.00005941229,0.000026566842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006767204,0.00090885157,0.0019319574,0.0023996239,0.00020840128,0.0009851636,0.0008751166,0.0010139777,0.0035418118],"category_scores_gemma":[0.0009819958,0.00029097724,0.00060175476,0.002257132,0.00041040775,0.001080005,0.0007754232,0.0018588719,0.0011558089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013500244,0.00006698688,0.000104221566,0.022596242,0.00016545343,0.0001403438,0.00003863789,0.000385366,0.0010927927,0.0022719905,0.022024453,0.95097864],"study_design_scores_gemma":[0.00009430505,0.00015813636,0.0006934064,0.008471993,0.00044272092,0.0009588999,0.000054407556,0.0001519404,0.00048774434,0.001736134,0.98672837,0.000021924083],"about_ca_topic_score_codex":0.0015415254,"about_ca_topic_score_gemma":0.0035368188,"teacher_disagreement_score":0.0035418118,"about_ca_system_score_codex":0.0006616839,"about_ca_system_score_gemma":0.0009574449,"threshold_uncertainty_score":0.011848509},"labels":[],"label_agreement":null},{"id":"W2302684203","doi":"10.1007/s40259-016-0166-5","title":"Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Panitumumab; KRAS; Cetuximab; Neuroblastoma RAS viral oncogene homolog; Colorectal cancer; Targeted therapy; Medicine; Oncology; Epidermal growth factor receptor; Oncogene; Cancer; Cancer research; Internal medicine","score_opus":0.05484679178644022,"score_gpt":0.39421890560359996,"score_spread":0.33937211381715976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2302684203","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001968802,0.9992212,0.0000556277,0.00010054084,0.000043962722,0.0000046796445,0.000011848916,0.0000024077835,0.0003629588],"genre_scores_gemma":[0.0012969685,0.99814117,0.00012450838,0.00014328175,0.000044454526,0.0000052476757,0.000020888678,7.545602e-7,0.0002226957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999881,0.000024935185,0.00002354516,0.000019781759,0.000037470723,0.0000132469195],"domain_scores_gemma":[0.9997843,0.00013067726,0.000041937754,0.0000044031462,0.000028297352,0.00001043128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004734423,0.0005508633,0.0015805381,0.0013866746,0.00014438716,0.00061273534,0.0006048705,0.00064746675,0.0024582096],"category_scores_gemma":[0.0005838561,0.00020493694,0.0007735485,0.0011350504,0.00026324458,0.0008037343,0.00039970814,0.0012176584,0.00055291015],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021215525,0.00009694436,0.00017244794,0.033825416,0.00030901394,0.00022724608,0.000043636108,0.0003852929,0.001959931,0.0018377369,0.011183241,0.94974697],"study_design_scores_gemma":[0.00022126685,0.000625871,0.0018482083,0.014082791,0.0014948138,0.0028215898,0.000102042104,0.00027211563,0.001615625,0.0021578285,0.97470915,0.000048720274],"about_ca_topic_score_codex":0.00067972334,"about_ca_topic_score_gemma":0.0023296447,"teacher_disagreement_score":0.0024582096,"about_ca_system_score_codex":0.00031611847,"about_ca_system_score_gemma":0.00061709154,"threshold_uncertainty_score":0.008223534},"labels":[],"label_agreement":null},{"id":"W2550419061","doi":"10.1007/s40259-016-0204-3","title":"Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Ontario Institute for Cancer Research","keywords":"Immune system; Immunology; Medicine; Adverse effect; Autoimmunity; Immunotherapy; Antibody; Immune checkpoint; Cytotoxic T cell; CTLA-4; Nivolumab; T cell; Biology; Pharmacology","score_opus":0.01959998934634755,"score_gpt":0.2869797453921792,"score_spread":0.26737975604583164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550419061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001521199,0.99912447,0.00007249033,0.0001124707,0.00008042719,0.000004675302,0.000019086287,0.0000030910644,0.00043121722],"genre_scores_gemma":[0.0016578332,0.99713385,0.00020522898,0.00033324628,0.00023949279,0.00000974922,0.00003808266,0.000001161743,0.00038138358],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9995963,0.00007957825,0.000109857465,0.00005940393,0.00012311598,0.00003178393],"domain_scores_gemma":[0.9990482,0.000520274,0.00029037087,0.000015814501,0.00010185212,0.000023536566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007471642,0.00071814714,0.0016485599,0.0013605432,0.00014516451,0.0007482008,0.00063967344,0.00083289575,0.0030868468],"category_scores_gemma":[0.001648647,0.0002235907,0.0010434466,0.0013338038,0.00025341913,0.0006640479,0.0005331107,0.0012547229,0.0005177026],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019804791,0.00006465288,0.00046671738,0.033052586,0.0004838093,0.00016378134,0.000024118914,0.00031228526,0.0007070447,0.0007701315,0.014186354,0.9495705],"study_design_scores_gemma":[0.00031435213,0.00076480507,0.0055608344,0.027300287,0.003694982,0.0040734033,0.00008351838,0.00041593926,0.0016385457,0.0022423642,0.95384824,0.000062622035],"about_ca_topic_score_codex":0.00056835567,"about_ca_topic_score_gemma":0.001768856,"teacher_disagreement_score":0.0030868468,"about_ca_system_score_codex":0.00037578412,"about_ca_system_score_gemma":0.0007313197,"threshold_uncertainty_score":0.010326505},"labels":[],"label_agreement":null},{"id":"W2613074462","doi":"10.1007/s40259-017-0219-4","title":"Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents","year":2017,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Concordance; Immunoassay; Cross-reactivity; Infliximab; Antibody; Rheumatoid arthritis; Internal medicine; Cross reactions; Immunology; Tumor necrosis factor alpha","score_opus":0.09935088227926661,"score_gpt":0.395455338091884,"score_spread":0.29610445581261735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613074462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99227905,0.00136754,0.0053711478,0.000018547518,0.000018095643,0.00006984218,0.00009142574,0.000038540766,0.00074586505],"genre_scores_gemma":[0.99432373,0.00024744496,0.0048142616,0.000045033434,0.000010540322,0.0000543804,0.00027086417,0.000005668292,0.0002280044],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99579537,0.0015215817,0.00036881125,0.00056372106,0.0015695989,0.00018100179],"domain_scores_gemma":[0.9966479,0.001105989,0.0012079413,0.00029563592,0.00061499083,0.0001275622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035271405,0.0006121531,0.00041562095,0.0013027944,0.00019945718,0.00046412298,0.00045010142,0.00075570046,0.00049641315],"category_scores_gemma":[0.004255688,0.00028732952,0.00053130556,0.0007922084,0.00037223313,0.0002330505,0.00035110675,0.00057458295,0.00020542956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005110908,0.00070270937,0.3128136,0.000488092,0.00060474215,0.00069271505,0.00070404523,0.0008658579,0.6508279,0.00019555292,0.0002075681,0.026786359],"study_design_scores_gemma":[0.00022536608,0.008570447,0.56530714,0.00006970631,0.0004248797,0.011364378,0.0002518904,0.011085341,0.40037668,0.000091464826,0.0021812536,0.000051388994],"about_ca_topic_score_codex":0.00054321846,"about_ca_topic_score_gemma":0.00042357616,"teacher_disagreement_score":0.0035271405,"about_ca_system_score_codex":0.00034207228,"about_ca_system_score_gemma":0.00015659709,"threshold_uncertainty_score":0.018653512},"labels":[],"label_agreement":null},{"id":"W2896685834","doi":"10.1007/s40259-018-0309-y","title":"Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood–Brain Barrier","year":2018,"lang":"en","type":"article","venue":"BioDrugs","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"Government of Canada","keywords":"Transcytosis; Biomanufacturing; Gene delivery; Blood–brain barrier; Transferrin receptor; Genetic enhancement; Nanocarriers; Medicine; Biology; Neuroscience; Computational biology; Immunology; Receptor; Central nervous system; Gene; Pharmacology; Drug; Biotechnology","score_opus":0.01483342197156779,"score_gpt":0.28583305590108515,"score_spread":0.27099963392951737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896685834","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0229716,0.61237425,0.30787197,0.011115004,0.0032564534,0.00033837755,0.0005474102,0.0013344578,0.040190537],"genre_scores_gemma":[0.14415826,0.64848715,0.16809435,0.007265332,0.0020717878,0.0007981043,0.00095067226,0.00024875623,0.02792556],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99886584,0.00014463475,0.00006414419,0.00019908321,0.00060552,0.00012079407],"domain_scores_gemma":[0.9995503,0.00011978974,0.0001081293,0.000039994302,0.00012773326,0.000054073702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00134978,0.00080941804,0.00088217086,0.0010893196,0.000564573,0.002190463,0.0012167252,0.0018927869,0.004348732],"category_scores_gemma":[0.0009144124,0.00050303986,0.0007922967,0.0007112581,0.0012323839,0.0035339866,0.0013883784,0.0032618449,0.003606134],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016503302,0.00020476234,0.00056158035,0.0063182195,0.000112911905,0.00077134283,0.0003164492,0.0013159957,0.5345763,0.120459944,0.017439695,0.31775773],"study_design_scores_gemma":[0.000053298703,0.00059083814,0.000768599,0.0006770309,0.00011454477,0.002996789,0.00017649072,0.0044805952,0.29206884,0.024752265,0.6732277,0.0000929537],"about_ca_topic_score_codex":0.00059040793,"about_ca_topic_score_gemma":0.00050548883,"teacher_disagreement_score":0.004348732,"about_ca_system_score_codex":0.0012050134,"about_ca_system_score_gemma":0.0010266169,"threshold_uncertainty_score":0.014547944},"labels":[],"label_agreement":null},{"id":"W2905052297","doi":"10.1007/s40259-018-0325-y","title":"Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies","year":2018,"lang":"en","type":"review","venue":"BioDrugs","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hereditary angioedema; Medicine; C1-inhibitor; Dosing; Tolerability; Kallikrein; Pharmacokinetics; Angioedema; Pharmacology; Pharmacodynamics; Internal medicine; Immunology; Adverse effect","score_opus":0.1589567030262765,"score_gpt":0.4415890634976389,"score_spread":0.28263236047136236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905052297","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043169028,0.99814796,0.00013345336,0.0003553816,0.00014808288,0.000037139645,0.00004521578,0.000008942582,0.00069211615],"genre_scores_gemma":[0.0030253597,0.9950971,0.00040703715,0.00077453343,0.00019244941,0.00006645028,0.000090885165,0.000004280395,0.00034196657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99965,0.00009473244,0.000083226885,0.0000491211,0.00009420909,0.00002867018],"domain_scores_gemma":[0.9988631,0.00063206407,0.00018053551,0.000022731258,0.00023309885,0.00006849526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017792745,0.0007539931,0.0019455336,0.0014921223,0.00026504323,0.0011654756,0.0012960013,0.0011677854,0.0032538318],"category_scores_gemma":[0.0020232373,0.00033771453,0.001750926,0.001110587,0.00039606856,0.0012422103,0.00045187544,0.0020169723,0.0007722559],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000853376,0.00031032134,0.00039789907,0.054377943,0.0006989256,0.00022491203,0.00012176657,0.00042192673,0.0028442082,0.0017485551,0.025117712,0.91288245],"study_design_scores_gemma":[0.0014948342,0.0031887498,0.0033596805,0.038604777,0.0036444354,0.002702722,0.00015129372,0.0005005554,0.0019218988,0.0018392885,0.9425056,0.000086117965],"about_ca_topic_score_codex":0.0007783326,"about_ca_topic_score_gemma":0.00169708,"teacher_disagreement_score":0.0032538318,"about_ca_system_score_codex":0.00053778,"about_ca_system_score_gemma":0.0009852195,"threshold_uncertainty_score":0.010885119},"labels":[],"label_agreement":null},{"id":"W2923414225","doi":"10.1007/s40259-019-00347-4","title":"PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review","year":2019,"lang":"en","type":"review","venue":"BioDrugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Ovarian cancer; Medicine; Cancer; Oncology; Pharmacotherapy; Internal medicine","score_opus":0.04552099282661187,"score_gpt":0.3574579287860135,"score_spread":0.31193693595940164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923414225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004631226,0.9992742,0.00004439388,0.0002192144,0.00010646999,0.000002990245,0.000015591715,0.0000035837047,0.00028728976],"genre_scores_gemma":[0.0003044223,0.9990715,0.00008446668,0.00022784439,0.00013189125,0.000003600189,0.000018166576,6.021462e-7,0.00015748746],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998072,0.000040208288,0.000035154477,0.00003770683,0.00006219978,0.000017550698],"domain_scores_gemma":[0.99935216,0.00039476616,0.00010404448,0.000009864425,0.00009980966,0.00003932517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007555384,0.00072799285,0.0016139707,0.0022050205,0.00024854956,0.0012512428,0.0009489486,0.0012838282,0.004116502],"category_scores_gemma":[0.0012915788,0.0002972089,0.0006773643,0.0021839007,0.00038736456,0.0013377303,0.0006805339,0.0019438103,0.0011126498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014539233,0.00007419826,0.00018782035,0.03720618,0.00016303307,0.00018018618,0.000043317945,0.00045389673,0.0009052202,0.0021468883,0.038158607,0.92033535],"study_design_scores_gemma":[0.00006407522,0.0002356062,0.00089685834,0.014745905,0.0005323395,0.0011601219,0.00007723273,0.00020412137,0.00030819647,0.001740909,0.9800047,0.000029931347],"about_ca_topic_score_codex":0.0011322588,"about_ca_topic_score_gemma":0.0031335037,"teacher_disagreement_score":0.004116502,"about_ca_system_score_codex":0.000623105,"about_ca_system_score_gemma":0.0012561375,"threshold_uncertainty_score":0.013771057},"labels":[],"label_agreement":null},{"id":"W2930500067","doi":"10.1007/s40259-019-00346-5","title":"Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting","year":2019,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Stockholms Läns Landsting","keywords":"Biosimilar; Market share; Medical prescription; Etanercept; Pharmacy; Prior authorization; Business; Reimbursement; Medicine; Quarter (Canadian coin); Marketing; Family medicine; Public economics; Health care; Economics; Economic growth; Nursing","score_opus":0.017447343844829443,"score_gpt":0.298849918284737,"score_spread":0.28140257443990757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2930500067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356866,0.0015041819,0.00035005042,0.0014490836,0.000019315099,0.00003172475,0.00020645434,0.00000963124,0.0028609016],"genre_scores_gemma":[0.99849427,0.00053492724,0.00038236057,0.00014535875,0.000010117068,0.00003490453,0.00011602988,0.000006014022,0.00027603138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99107236,0.0047374885,0.00077424047,0.00090736675,0.0012955025,0.0012131457],"domain_scores_gemma":[0.9632719,0.020982381,0.010590918,0.00069230434,0.0028717187,0.0015907624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076773274,0.00014238582,0.00030308552,0.0020761983,0.0011475453,0.004288399,0.0007443783,0.00073444756,0.0023220289],"category_scores_gemma":[0.025135443,0.0002322504,0.00045609978,0.0026520807,0.0016374484,0.0013458085,0.0021101777,0.0006766716,0.00020695794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007325817,0.00040555085,0.8967289,0.0010440085,0.00023928481,0.0008626717,0.03924072,0.0013707693,0.0011246495,0.005297362,0.0033175673,0.04963598],"study_design_scores_gemma":[0.000039351507,0.00026488162,0.93671364,0.00062096555,0.00012740273,0.00025530206,0.048875693,0.00048702882,0.0005988786,0.0007786952,0.011200595,0.000037617927],"about_ca_topic_score_codex":0.04198865,"about_ca_topic_score_gemma":0.04106987,"teacher_disagreement_score":0.04198865,"about_ca_system_score_codex":0.0070782583,"about_ca_system_score_gemma":0.0092390645,"threshold_uncertainty_score":0.083488464},"labels":[],"label_agreement":null},{"id":"W2954341438","doi":"10.1007/s40259-019-00361-6","title":"Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis","year":2019,"lang":"en","type":"review","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Ankylosing spondylitis; Tolerability; Interleukin 17; Immunology; Disease; Interleukin 23; Interleukin 22; Clinical trial; Psoriasis Area and Severity Index; Spondylitis; Interleukin; Dermatology; Internal medicine; Cytokine; Adverse effect","score_opus":0.04080093537706545,"score_gpt":0.28074100667087143,"score_spread":0.23994007129380598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954341438","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014949338,0.9980856,0.00016627199,0.0003253241,0.00043457202,0.000006122282,0.000025524692,0.000010436653,0.0007967675],"genre_scores_gemma":[0.0012500605,0.99587375,0.00027660409,0.00063596043,0.00031176556,0.000009449,0.00006275728,0.000002707377,0.0015768809],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998436,0.000023562921,0.00001978532,0.000024727853,0.00006389619,0.000024437317],"domain_scores_gemma":[0.9998165,0.0000700831,0.00003418067,0.0000046847463,0.000046584097,0.00002797594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055717834,0.00082189357,0.0012266483,0.0012931001,0.00019005816,0.00088211626,0.0007745484,0.0010717303,0.0025499335],"category_scores_gemma":[0.00052201503,0.00021590084,0.00042460667,0.00096809905,0.00037229396,0.00089329033,0.0005427734,0.002630688,0.0018699985],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017999209,0.00008026869,0.00007837652,0.005475052,0.000076966055,0.00013745435,0.000024284544,0.00026976215,0.0018601158,0.002655552,0.040957972,0.9482042],"study_design_scores_gemma":[0.000110090405,0.00017681508,0.0004222278,0.0014114106,0.000111579815,0.00092078856,0.000019574622,0.000111635796,0.0006845193,0.0010758265,0.9949399,0.000015674252],"about_ca_topic_score_codex":0.0010116161,"about_ca_topic_score_gemma":0.0024369902,"teacher_disagreement_score":0.0025499335,"about_ca_system_score_codex":0.00056810165,"about_ca_system_score_gemma":0.0008606476,"threshold_uncertainty_score":0.008530438},"labels":[],"label_agreement":null},{"id":"W2961547340","doi":"10.1007/s40259-019-00366-1","title":"Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine","year":2019,"lang":"en","type":"review","venue":"BioDrugs","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Inflammatory bowel disease; Ulcerative colitis; Drug; Therapeutic drug monitoring; Personalized medicine; Monoclonal antibody; Pharmacodynamics; Dosing; Pharmacokinetics; Crohn's disease; Precision medicine; Efficacy; Disease; Pharmacotherapy; Pharmacology; Immunology; Intensive care medicine; Internal medicine; Bioinformatics; Antibody; Pathology","score_opus":0.10793292692231948,"score_gpt":0.40406737536733095,"score_spread":0.29613444844501147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961547340","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015175434,0.9993773,0.00006024288,0.00016227573,0.00005097056,0.0000015268822,0.000014817826,0.000001836324,0.00017925237],"genre_scores_gemma":[0.0010637378,0.99834824,0.00013294857,0.00017579364,0.00013103716,0.0000034300658,0.000020832485,5.4103674e-7,0.0001234108],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997662,0.00006239453,0.000041938994,0.000049525148,0.00006241733,0.000017494784],"domain_scores_gemma":[0.99900085,0.00069168565,0.00015529532,0.00001438862,0.00011264559,0.000025135036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007754379,0.0005808015,0.0016113105,0.0012586447,0.00011661015,0.0010134368,0.0005593006,0.0009280935,0.0022694373],"category_scores_gemma":[0.0016013517,0.00018364163,0.00085378165,0.0015731578,0.0003599809,0.0008082103,0.0004050761,0.0012563086,0.0005372436],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002450831,0.000101810634,0.0014538784,0.020934956,0.0005278279,0.0001669297,0.00003360222,0.00041491326,0.00088004617,0.0018979346,0.010872272,0.9624707],"study_design_scores_gemma":[0.00020299308,0.0006634135,0.012791557,0.02115396,0.0034281753,0.0029388582,0.00020514277,0.0006631696,0.001475084,0.007016886,0.9493522,0.00010849284],"about_ca_topic_score_codex":0.0012678003,"about_ca_topic_score_gemma":0.0022301015,"teacher_disagreement_score":0.0022694373,"about_ca_system_score_codex":0.0004702292,"about_ca_system_score_gemma":0.0009233843,"threshold_uncertainty_score":0.007592082},"labels":[],"label_agreement":null},{"id":"W3094124122","doi":"10.1007/s40259-020-00451-w","title":"Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease","year":2020,"lang":"en","type":"article","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministère de l'Agriculture, des Pêcheries et de l'Alimentation; University of Calgary; Western University","funders":"","keywords":"Ustekinumab; Medicine; Interleukin 23; Ulcerative colitis; Inflammatory bowel disease; Crohn's disease; Immunology; Inflammation; Immune system; Pathogenesis; Disease; Clinical trial; Interleukin 17; Internal medicine; Tumor necrosis factor alpha; Infliximab","score_opus":0.06456502656389661,"score_gpt":0.31679348668401647,"score_spread":0.25222846012011985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094124122","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7521648,0.22178006,0.0018256078,0.0059286053,0.0021862225,0.0027543716,0.0011695885,0.00021840748,0.0119723035],"genre_scores_gemma":[0.93302536,0.05318913,0.002149499,0.002943148,0.00087972183,0.0021435055,0.00091372454,0.000034157085,0.0047216974],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993818,0.00034824043,0.00004527171,0.000057127218,0.000053049276,0.000114549504],"domain_scores_gemma":[0.9993389,0.000260928,0.0001047248,0.00003162459,0.000051127554,0.00021263913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021613261,0.0007554485,0.0025737113,0.0005268709,0.00046684494,0.00094944274,0.0005868954,0.0013614927,0.005026446],"category_scores_gemma":[0.0011997456,0.0002794421,0.0013650261,0.00048950216,0.00071834907,0.00067254575,0.00031142385,0.0032615333,0.00067977],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5666901,0.015726428,0.0013940387,0.0058620204,0.0021797733,0.00033530392,0.00022727948,0.0014380397,0.027775453,0.0011888728,0.0051082983,0.37207443],"study_design_scores_gemma":[0.5893514,0.37187475,0.0055614896,0.00080889574,0.00158383,0.0003402484,0.0001886766,0.0006012134,0.007146071,0.0007176243,0.021777913,0.000047814505],"about_ca_topic_score_codex":0.00060660706,"about_ca_topic_score_gemma":0.0014894074,"teacher_disagreement_score":0.005026446,"about_ca_system_score_codex":0.00051669637,"about_ca_system_score_gemma":0.0007640546,"threshold_uncertainty_score":0.016815186},"labels":[],"label_agreement":null},{"id":"W3132376226","doi":"10.1007/s40259-020-00464-5","title":"Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists","year":2021,"lang":"en","type":"article","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen UK; Arthritis Society; Psoriasis Association","keywords":"Medicine; Nice; Specialty; Excellence; Equity (law); Alternative medicine; Health care; Family medicine; Intensive care medicine; Political science","score_opus":0.04720052022437258,"score_gpt":0.30890214784455794,"score_spread":0.26170162762018534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132376226","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42768407,0.017598912,0.013865608,0.5150837,0.003888055,0.0008017283,0.00011285846,0.00014895428,0.020816252],"genre_scores_gemma":[0.9453449,0.0052809,0.01279271,0.033136796,0.00044880752,0.00025417862,0.00006764003,0.000056755558,0.002617232],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.84573364,0.10238462,0.015295331,0.0056247595,0.020811789,0.010149809],"domain_scores_gemma":[0.81215054,0.08415119,0.013776398,0.005182517,0.045247145,0.039492257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11027591,0.00044016066,0.00127994,0.0024022118,0.0070759393,0.010321853,0.0025606188,0.008281696,0.003076472],"category_scores_gemma":[0.13095166,0.001123091,0.0010847372,0.0014537589,0.011478565,0.008362637,0.017988287,0.009574613,0.00070587633],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027710278,0.00028253996,0.029960455,0.0030659377,0.00020265394,0.009190913,0.77021396,0.0008846463,0.00538621,0.0125062885,0.053645156,0.114384204],"study_design_scores_gemma":[0.00014706695,0.00063013355,0.032265678,0.0079904,0.00012903824,0.00879867,0.7420029,0.0029738462,0.0017693343,0.02357633,0.17919809,0.0005185399],"about_ca_topic_score_codex":0.0094597675,"about_ca_topic_score_gemma":0.011030012,"teacher_disagreement_score":0.11027591,"about_ca_system_score_codex":0.011222268,"about_ca_system_score_gemma":0.032886475,"threshold_uncertainty_score":0.5832017},"labels":[],"label_agreement":null},{"id":"W3167186946","doi":"10.1007/s40259-021-00486-7","title":"Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy","year":2021,"lang":"en","type":"review","venue":"BioDrugs","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Women and Children's Health Research Institute","keywords":"Spinal muscular atrophy; Duchenne muscular dystrophy; SMA*; Exon skipping; Medicine; Dystrophin; Neuromuscular disease; Muscular dystrophy; Antisense therapy; Motor neuron; Weakness; Bioinformatics; Genetic enhancement; Exon; Internal medicine; Disease; Biology; Surgery; Genetics; Gene; microRNA; Alternative splicing","score_opus":0.061684812040391196,"score_gpt":0.4081047040783568,"score_spread":0.34641989203796564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167186946","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000062501545,0.9995658,0.000060456565,0.000060105427,0.00005957407,0.0000034081215,0.000016963719,0.0000030077542,0.00016808874],"genre_scores_gemma":[0.0003012544,0.99923265,0.00013808264,0.000115648654,0.00004608823,0.0000052065698,0.000026725435,9.53879e-7,0.0001333672],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997439,0.00004389144,0.000061073784,0.000044436358,0.00008504173,0.000021722226],"domain_scores_gemma":[0.9993594,0.00045039022,0.00007626427,0.000010957255,0.00007789032,0.00002505267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097576686,0.00090537407,0.0026027581,0.0022979248,0.00020414396,0.0011862852,0.0010421984,0.0012662986,0.0033758776],"category_scores_gemma":[0.001131295,0.00035064996,0.0010201095,0.0021634356,0.00044041793,0.0012093663,0.00060162746,0.0018044164,0.0011960941],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022397088,0.00009256473,0.00016194646,0.068195015,0.00031527356,0.00023802818,0.00006806769,0.00036609604,0.002950395,0.0018699542,0.01791592,0.9076027],"study_design_scores_gemma":[0.00012641218,0.00033278315,0.0012102867,0.016814452,0.001273278,0.0017705992,0.00008826651,0.00016234773,0.0011491824,0.0014720896,0.97555315,0.00004719212],"about_ca_topic_score_codex":0.00096689287,"about_ca_topic_score_gemma":0.002097021,"teacher_disagreement_score":0.0033758776,"about_ca_system_score_codex":0.0004353566,"about_ca_system_score_gemma":0.0010430024,"threshold_uncertainty_score":0.011293471},"labels":[],"label_agreement":null},{"id":"W3212746417","doi":"10.1007/s40259-021-00507-5","title":"Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; American Gastroenterological Association","keywords":"Medicine; Inflammatory bowel disease; Drug; Meta-analysis; Antibody; Pharmacotherapy; Pharmacology; Disease; Immunology; Internal medicine","score_opus":0.041898538352883714,"score_gpt":0.331977762686112,"score_spread":0.2900792243332283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212746417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021974272,0.99715614,0.00013378053,0.00006510151,0.00005677491,0.00004798645,0.00022867591,0.0000061510636,0.00010796848],"genre_scores_gemma":[0.076968275,0.9206518,0.000881135,0.00065196096,0.00012985757,0.00016231344,0.00032416766,0.000010207759,0.00022034036],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970651,0.0011036171,0.00091407256,0.00039277307,0.00037241486,0.0001520154],"domain_scores_gemma":[0.99344254,0.0045593437,0.0014015937,0.00016727664,0.00033276863,0.00009651242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046840473,0.0015725116,0.010220447,0.0028637266,0.0003004585,0.0018414408,0.0013186547,0.0017575292,0.004229326],"category_scores_gemma":[0.010367276,0.00094495935,0.017027056,0.0045954883,0.0004918813,0.001175546,0.0013466022,0.0014566324,0.00028469268],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023114008,0.000045024484,0.00618287,0.57672393,0.37893763,0.00015504625,0.000094933996,0.0004100924,0.00035451687,0.00017438635,0.0012743142,0.033335682],"study_design_scores_gemma":[0.0011669755,0.00029328206,0.009057824,0.038840264,0.9454158,0.00018846965,0.0000796501,0.00013560688,0.00012654305,0.00024791076,0.004408023,0.000039709168],"about_ca_topic_score_codex":0.004447877,"about_ca_topic_score_gemma":0.015751252,"teacher_disagreement_score":0.010220447,"about_ca_system_score_codex":0.0012144332,"about_ca_system_score_gemma":0.0017811143,"threshold_uncertainty_score":0.02477187},"labels":[],"label_agreement":null},{"id":"W34856137","doi":"10.2165/0063030-200822060-00003","title":"Embryonic Stem Cell Transplantation","year":2008,"lang":"en","type":"review","venue":"BioDrugs","topic":"Pluripotent Stem Cells Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Transplantation; Stem cell; Medicine; Myocyte; Progenitor cell; Embryonic stem cell; Cell therapy; Angiogenesis; Stem-cell therapy; Internal medicine; Pathology; Biology; Cell biology","score_opus":0.03194788123583159,"score_gpt":0.2997860719150581,"score_spread":0.26783819067922654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W34856137","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00096094306,0.95276165,0.009363221,0.0012436305,0.0039665583,0.000068680616,0.00013047294,0.000170885,0.031333968],"genre_scores_gemma":[0.0050960635,0.9479845,0.0054266043,0.0019935574,0.0011256348,0.00009138682,0.00032328727,0.00003352546,0.037925422],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998447,0.00002172489,0.000013400792,0.00003419409,0.00006974856,0.00001625227],"domain_scores_gemma":[0.9998921,0.000042594605,0.000012796968,0.0000116799965,0.000025699634,0.000015108036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006651674,0.0011200855,0.0011735728,0.0013314069,0.0002799306,0.00078317564,0.00095109554,0.0011257714,0.0065802983],"category_scores_gemma":[0.00036589493,0.00025928454,0.00036184886,0.0010395126,0.0008525045,0.00085377804,0.0008508879,0.0018438523,0.0042748726],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061723644,0.00007341058,0.00010237083,0.0024658095,0.000027347265,0.00042484334,0.000024453548,0.0003035729,0.0086323405,0.011068046,0.045805436,0.9310108],"study_design_scores_gemma":[0.000017251969,0.000028716055,0.00022239017,0.00045855754,0.000026470543,0.0011770108,0.000014547495,0.000073312156,0.0034479713,0.0026015984,0.99192315,0.00000898585],"about_ca_topic_score_codex":0.0005785859,"about_ca_topic_score_gemma":0.0014264047,"teacher_disagreement_score":0.0065802983,"about_ca_system_score_codex":0.0005809828,"about_ca_system_score_gemma":0.0006087254,"threshold_uncertainty_score":0.022013247},"labels":[],"label_agreement":null},{"id":"W4200032396","doi":"10.1007/s40259-021-00512-8","title":"A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn’s Disease","year":2021,"lang":"en","type":"article","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"UCB Pharma; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Certolizumab pegol; Medicine; Calprotectin; Internal medicine; Confidence interval; Crohn's disease; Odds ratio; Area under the curve; Population; Placebo; Gastroenterology; Pharmacokinetics; Inflammatory bowel disease; Disease; Adalimumab","score_opus":0.03376399519034329,"score_gpt":0.3145580637676515,"score_spread":0.2807940685773082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200032396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75252736,0.0019049192,0.22627689,0.005897974,0.00037619326,0.00029982705,0.004944946,0.0012234489,0.0065484657],"genre_scores_gemma":[0.987958,0.0001987481,0.008407843,0.0002072422,0.00012560026,0.000107786975,0.0014151544,0.000018833758,0.0015608064],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9993148,0.00027494194,0.000058785903,0.00016265477,0.00009809828,0.00009082711],"domain_scores_gemma":[0.9898319,0.008593773,0.0005710559,0.00016120133,0.0005311822,0.00031070117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027934348,0.00078689813,0.0012693639,0.0012656341,0.0003388324,0.001280751,0.0008821217,0.0012297642,0.003027642],"category_scores_gemma":[0.009707935,0.00039204943,0.0008603754,0.0005355163,0.00032770267,0.00050822797,0.00054096925,0.0012513603,0.0007591517],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025478841,0.00073912455,0.2320299,0.00013797692,0.0005989227,0.0008031936,0.00009572223,0.65325975,0.001225671,0.0027690867,0.008124491,0.09766827],"study_design_scores_gemma":[0.000055152508,0.00012453024,0.00673287,0.000012108086,0.00007163628,0.00011241415,0.000012138782,0.99138767,0.00013595862,0.0010529167,0.00029346344,0.000009222536],"about_ca_topic_score_codex":0.0069106417,"about_ca_topic_score_gemma":0.00324665,"teacher_disagreement_score":0.0069106417,"about_ca_system_score_codex":0.0006469563,"about_ca_system_score_gemma":0.0010174176,"threshold_uncertainty_score":0.01477325},"labels":[],"label_agreement":null},{"id":"W4310776690","doi":"10.1007/s40259-022-00568-0","title":"The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries","year":2022,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; China; Medicine; Biopharmaceutical; European union; Business; Product (mathematics); International trade; Biotechnology; Geography","score_opus":0.02814807893878446,"score_gpt":0.29967549266217763,"score_spread":0.2715274137233932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310776690","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97893286,0.0120786745,0.0003150095,0.0008543514,0.000011490415,0.000040130628,0.003088214,0.000021453865,0.0046577896],"genre_scores_gemma":[0.9909456,0.0055112904,0.0007279196,0.00031635942,0.000016397702,0.000039523045,0.0020891754,0.000009298116,0.00034440955],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980439,0.00047820373,0.00039385384,0.00040458085,0.00042670697,0.00025282687],"domain_scores_gemma":[0.99070716,0.0018865196,0.006012295,0.00018142542,0.00072257675,0.00049005466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002221211,0.0002107106,0.00025240442,0.0047309482,0.00041874676,0.001408647,0.00030705612,0.00038444562,0.002656759],"category_scores_gemma":[0.0036073648,0.00017311773,0.00056812225,0.006942431,0.00042702653,0.0015389118,0.0010717149,0.0003563484,0.0003592392],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017023298,0.000035125206,0.9732887,0.00028723513,0.00014324243,0.0002796309,0.0008595072,0.0001112922,0.0005131601,0.00064273196,0.0012436874,0.022425424],"study_design_scores_gemma":[0.00001295163,0.00013636268,0.98301214,0.0003450369,0.00014327258,0.001432911,0.0036850874,0.0001940083,0.00048523713,0.00016395732,0.010373971,0.000015021446],"about_ca_topic_score_codex":0.0017998308,"about_ca_topic_score_gemma":0.0023005283,"teacher_disagreement_score":0.0047309482,"about_ca_system_score_codex":0.0005488165,"about_ca_system_score_gemma":0.0007771075,"threshold_uncertainty_score":0.011747003},"labels":[],"label_agreement":null},{"id":"W4360601016","doi":"10.1007/s40259-023-00589-3","title":"Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health and Medical Research Fund; Medical Research Council; University of Hong Kong; National Institute for Health and Care Research; Australian Government; National Health and Medical Research Council; European Commission; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Biosimilar; Infliximab; Medicine; Interrupted time series; Interrupted Time Series Analysis; Consumption (sociology); Demography; Internal medicine; Tumor necrosis factor alpha","score_opus":0.02306556960911271,"score_gpt":0.3292944411009679,"score_spread":0.3062288714918552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360601016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773514,0.00031549955,0.0006400492,0.0000589291,0.000010370482,0.000012449008,0.000939257,0.000008410103,0.00027997035],"genre_scores_gemma":[0.99762255,0.00015721588,0.00043563198,0.00002936119,0.0000075990883,0.000022957374,0.0014095603,0.0000051617626,0.0003100774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762005,0.0011036755,0.00022522354,0.00047106994,0.00033867988,0.00024122],"domain_scores_gemma":[0.99186724,0.0027623174,0.003677534,0.0004878636,0.00085143565,0.00035365348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031244252,0.0002679264,0.00055726705,0.0007503697,0.00014460692,0.00091761287,0.000535585,0.0004478616,0.0010668737],"category_scores_gemma":[0.007930735,0.00020242608,0.001606846,0.0017333159,0.00030056993,0.00040787473,0.0004850742,0.000784192,0.00017706226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018042892,0.00014872148,0.9853976,0.00009704108,0.0012958333,0.0002441025,0.00040252588,0.0035538746,0.00089346484,0.00015681132,0.0002875194,0.005718084],"study_design_scores_gemma":[0.000026932648,0.00035242594,0.9887228,0.000017556005,0.00043558347,0.0001000949,0.00029432715,0.009161774,0.00036117525,0.000045375076,0.0004659875,0.000015992853],"about_ca_topic_score_codex":0.025106484,"about_ca_topic_score_gemma":0.011426119,"teacher_disagreement_score":0.025106484,"about_ca_system_score_codex":0.00083728065,"about_ca_system_score_gemma":0.00071218464,"threshold_uncertainty_score":0.04992068},"labels":[],"label_agreement":null},{"id":"W4362507438","doi":"10.1007/s40259-023-00592-8","title":"Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"ZonMw","keywords":"Medicine; Internal medicine; Rheumatoid arthritis; Etanercept; Cohort; Adverse effect; Adalimumab; Infliximab; Rituximab; Discontinuation; Disease; Pediatrics","score_opus":0.12201455600774835,"score_gpt":0.35177126870530334,"score_spread":0.229756712697555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362507438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949366,0.00094468845,0.00014022343,0.00008874188,0.0000054144716,0.000062953884,0.0028808417,0.0000035962473,0.00093689933],"genre_scores_gemma":[0.9943932,0.000691981,0.00024415978,0.00010011423,0.000014064755,0.00013749844,0.0041455394,0.000005491128,0.0002678999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828476,0.0007665659,0.00029323617,0.00017781586,0.00038524883,0.00009235194],"domain_scores_gemma":[0.9930112,0.0015878497,0.004325492,0.00027134636,0.0004546947,0.0003495112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018732267,0.00015856771,0.000404857,0.00062528916,0.0001974646,0.0004748914,0.0002518537,0.00032844584,0.001196297],"category_scores_gemma":[0.0076643266,0.00012765956,0.00039634993,0.0012876679,0.00015366919,0.00031173872,0.00044085432,0.00027596156,0.00023761173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075224997,0.00009630576,0.9882758,0.0001193024,0.00014312463,0.00013705704,0.0005264069,0.000069353206,0.00032243854,0.000019364736,0.0008240898,0.0087144105],"study_design_scores_gemma":[0.0000856941,0.00026077326,0.9969068,0.000040839986,0.000055670396,0.00038174613,0.00021538319,0.00015199633,0.0000979933,0.000008922226,0.0017884455,0.0000058380833],"about_ca_topic_score_codex":0.008776056,"about_ca_topic_score_gemma":0.010123504,"teacher_disagreement_score":0.008776056,"about_ca_system_score_codex":0.00065171404,"about_ca_system_score_gemma":0.000423082,"threshold_uncertainty_score":0.017449975},"labels":[],"label_agreement":null},{"id":"W4388902238","doi":"10.1007/s40259-023-00630-5","title":"Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Celltrion","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Clinical endpoint; Biosimilar; Dosing; Adverse effect; Randomized controlled trial; Psoriasis; Tolerability; Internal medicine; Dermatology; Adalimumab","score_opus":0.04463726408912411,"score_gpt":0.3397974502253265,"score_spread":0.2951601861362024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388902238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933629,0.0014287571,0.0008101392,0.00021964122,0.0001303444,0.0027187723,0.00047116444,0.00008286766,0.0007754336],"genre_scores_gemma":[0.9919012,0.0010758861,0.0014505684,0.00056229165,0.00025001232,0.0024384644,0.0007450014,0.000038600527,0.0015379832],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99781346,0.0012914651,0.00014739383,0.00026721286,0.00024168935,0.00023871507],"domain_scores_gemma":[0.99634355,0.0009999048,0.0008691115,0.00041039067,0.00028502205,0.0010920459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054668654,0.0018145769,0.0039692223,0.00051018153,0.00062363496,0.0012913978,0.0014280621,0.0028587978,0.004673449],"category_scores_gemma":[0.0037709915,0.0009848516,0.0029836628,0.0004648465,0.0021871803,0.0015560025,0.0005095502,0.004577389,0.0010647938],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93650484,0.035139088,0.00060982193,0.0004668491,0.00072162447,0.00005629962,0.00016293851,0.00047077303,0.013636046,0.00006451208,0.0005257823,0.011641415],"study_design_scores_gemma":[0.7191408,0.2754957,0.002514612,0.000024623945,0.00034190435,0.00007137042,0.000023942077,0.0003392352,0.0016005415,0.000096828844,0.00032839208,0.000022027296],"about_ca_topic_score_codex":0.0005988009,"about_ca_topic_score_gemma":0.0009649368,"teacher_disagreement_score":0.0054668654,"about_ca_system_score_codex":0.00086395396,"about_ca_system_score_gemma":0.0018310595,"threshold_uncertainty_score":0.028911889},"labels":[],"label_agreement":null},{"id":"W4389486878","doi":"10.1007/s40259-023-00636-z","title":"Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Research Foundation of Korea","keywords":"Biosimilar; Adalimumab; Medicine; Significant difference; Intensive care medicine; Internal medicine; Rheumatoid arthritis","score_opus":0.027742553902886852,"score_gpt":0.2830068196293937,"score_spread":0.25526426572650684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389486878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411136,0.0018544547,0.0016897279,0.00019887788,0.00008854693,0.00008992805,0.0015278141,0.000017120092,0.00042209832],"genre_scores_gemma":[0.9978067,0.00017204121,0.0005630361,0.00010705197,0.000019031379,0.00007763162,0.0010891387,0.00000772869,0.00015757229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97754014,0.017138707,0.0013295729,0.0018163368,0.0008474426,0.0013277438],"domain_scores_gemma":[0.98138404,0.012543625,0.0036628086,0.0012709737,0.0005837509,0.0005547569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01461385,0.0007517425,0.0018904716,0.0012328095,0.00024337503,0.001320906,0.0010521736,0.0007234039,0.0021035632],"category_scores_gemma":[0.017406229,0.00048645728,0.009574703,0.0016324399,0.0007850148,0.0006888155,0.0017278707,0.0015252627,0.00016694097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011280404,0.00031728268,0.92788273,0.0006641876,0.037668973,0.0005084685,0.00020331283,0.011533719,0.0011930489,0.00066639774,0.0007921854,0.0072893673],"study_design_scores_gemma":[0.0009675086,0.0037663868,0.9416162,0.00025425354,0.015450184,0.00040551135,0.0011488626,0.030648248,0.0017588993,0.00063736475,0.0032457556,0.00010083373],"about_ca_topic_score_codex":0.008967282,"about_ca_topic_score_gemma":0.0044038245,"teacher_disagreement_score":0.01461385,"about_ca_system_score_codex":0.00073396345,"about_ca_system_score_gemma":0.00076251983,"threshold_uncertainty_score":0.07728636},"labels":[],"label_agreement":null},{"id":"W4402620082","doi":"10.1007/s40259-024-00677-y","title":"Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure","year":2024,"lang":"en","type":"review","venue":"BioDrugs","topic":"Mosquito-borne diseases and control","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases; National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences","keywords":"Chikungunya; Medicine; Clinical trial; European union; Virology; Alphavirus; Licensure; Virus; Internal medicine; Business","score_opus":0.0731524147698617,"score_gpt":0.46887543996479425,"score_spread":0.3957230251949325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402620082","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033417833,0.9979298,0.00013546509,0.0003774991,0.00016541009,0.000024927098,0.00005313669,0.000007426865,0.0009720768],"genre_scores_gemma":[0.0013734632,0.99712366,0.0002985034,0.00048212198,0.00013524546,0.000042114578,0.00008212586,0.0000032391358,0.00045954017],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995011,0.00012695146,0.0001236067,0.00005816542,0.00014890106,0.000041319276],"domain_scores_gemma":[0.9989594,0.00056222064,0.00017765592,0.000021464604,0.00023237265,0.000046858062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015849076,0.00070034066,0.0012088381,0.0018506179,0.00024059654,0.0010727951,0.0008159959,0.00106768,0.0035634942],"category_scores_gemma":[0.0021836408,0.00035339818,0.0012393905,0.0013850256,0.00034473863,0.0012138746,0.0004972822,0.0014860526,0.0011956168],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032046848,0.00013850986,0.00027070902,0.055281475,0.00026662496,0.00031206862,0.00018384607,0.0004185187,0.0030276426,0.002480383,0.028529482,0.9087703],"study_design_scores_gemma":[0.00007958649,0.00059659366,0.001128133,0.017817445,0.0005587599,0.0009656093,0.000070139315,0.00010141332,0.0010453733,0.00087643677,0.9767328,0.000027676198],"about_ca_topic_score_codex":0.0010849051,"about_ca_topic_score_gemma":0.0017969462,"teacher_disagreement_score":0.0035634942,"about_ca_system_score_codex":0.00055134814,"about_ca_system_score_gemma":0.0014713213,"threshold_uncertainty_score":0.011921048},"labels":[],"label_agreement":null},{"id":"W4404773045","doi":"10.1007/s40259-024-00687-w","title":"Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa","year":2024,"lang":"en","type":"review","venue":"BioDrugs","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Fundação para a Ciência e a Tecnologia; Universidade do Porto","keywords":"Medicine; Secukinumab; Hidradenitis suppurativa; Clinical trial; Dermatology; Quality of life (healthcare); Psoriasis; Pharmacology; Intensive care medicine; Disease; Internal medicine; Psoriatic arthritis","score_opus":0.06812192845542084,"score_gpt":0.37866150478802446,"score_spread":0.31053957633260365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404773045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015547565,0.99649256,0.00015510734,0.00029727674,0.00018665852,0.00001312993,0.000036476064,0.000014968247,0.0012489015],"genre_scores_gemma":[0.019013355,0.97756094,0.0006296946,0.00082236365,0.0004566487,0.00003944538,0.00017275465,0.000005202687,0.0012996645],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99982554,0.00005072941,0.000029767241,0.00002054072,0.00005002787,0.000023310136],"domain_scores_gemma":[0.99987376,0.000054846372,0.000033631244,0.0000028338407,0.000022683109,0.000012280037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003424248,0.00031212205,0.0006315657,0.0006675899,0.00014080587,0.00046839457,0.00031988142,0.00042928886,0.002562574],"category_scores_gemma":[0.00038167488,0.00009087914,0.0005452389,0.00041024797,0.00014171386,0.00037364903,0.00028966524,0.0011544472,0.00062623265],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006990691,0.00022933322,0.0004371497,0.016218146,0.00026262458,0.0005759985,0.000105397405,0.00043761294,0.006572613,0.001750561,0.01624686,0.95646477],"study_design_scores_gemma":[0.0006757308,0.0018797737,0.0048898924,0.008005496,0.00081272423,0.0047826646,0.00016144734,0.00047277202,0.0041059027,0.0018208848,0.97234803,0.000044636614],"about_ca_topic_score_codex":0.00031701758,"about_ca_topic_score_gemma":0.0011534728,"teacher_disagreement_score":0.002562574,"about_ca_system_score_codex":0.00020331568,"about_ca_system_score_gemma":0.00035085293,"threshold_uncertainty_score":0.008572698},"labels":[],"label_agreement":null},{"id":"W4407184001","doi":"10.1007/s40259-025-00706-4","title":"TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review","year":2025,"lang":"en","type":"review","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Inflammatory bowel disease; Medicine; Molecular medicine; Internal medicine; Disease; Pharmacology; Bioinformatics; Biology","score_opus":0.011370653430036959,"score_gpt":0.29015501408293426,"score_spread":0.2787843606528973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407184001","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000111320995,0.9984749,0.00016280272,0.00028747038,0.00031385475,0.000010987669,0.000042715776,0.000014229328,0.0005817768],"genre_scores_gemma":[0.0006109087,0.99793917,0.00022935015,0.00041020632,0.00016907962,0.000016117627,0.00006471963,0.0000028936222,0.0005576305],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999828,0.000031491265,0.000024009141,0.000030691474,0.00005631669,0.000029645636],"domain_scores_gemma":[0.9996629,0.00016514362,0.000045332927,0.000008665343,0.00007359489,0.000044421315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084438367,0.0011193719,0.0023413405,0.0017982698,0.00024889034,0.0012527471,0.0010798887,0.0013369527,0.0053324834],"category_scores_gemma":[0.0009717456,0.00035997076,0.00097472384,0.0015530125,0.00043968298,0.0011566194,0.0008241609,0.0031777266,0.002214956],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037120824,0.00016512658,0.00010175569,0.019131314,0.00019878786,0.00018643517,0.000037682043,0.0005532205,0.002511516,0.0033475226,0.06051309,0.91288245],"study_design_scores_gemma":[0.00019672014,0.00043440965,0.00046703324,0.004755829,0.00044543803,0.0006075406,0.00003745422,0.00017947172,0.00079215225,0.002054034,0.98999983,0.000030251735],"about_ca_topic_score_codex":0.00089438935,"about_ca_topic_score_gemma":0.0024147285,"teacher_disagreement_score":0.0053324834,"about_ca_system_score_codex":0.0006006125,"about_ca_system_score_gemma":0.001202394,"threshold_uncertainty_score":0.017838895},"labels":[],"label_agreement":null},{"id":"W4407922422","doi":"10.1007/s40259-025-00709-1","title":"Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries","year":2025,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of Calgary; University of British Columbia; University of Toronto; Providence Health Care","funders":"Canadian Institutes of Health Research; National Research Foundation of Korea; Michael Smith Health Research BC","keywords":"Biosimilar; Infliximab; Adalimumab; Etanercept; Descriptive statistics; Medicine; Antirheumatic Agents; Pharmacology; Business; Rheumatoid arthritis; Internal medicine; Tumor necrosis factor alpha","score_opus":0.011238142126732919,"score_gpt":0.28803591462183653,"score_spread":0.2767977724951036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407922422","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93913084,0.02457594,0.0007995826,0.0024091124,0.00004682718,0.000089923225,0.012420684,0.000029330931,0.020497765],"genre_scores_gemma":[0.9884008,0.008174678,0.00027568053,0.00034463155,0.000019054092,0.00008234676,0.0020316108,0.00001294414,0.00065821526],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946096,0.0022677956,0.0005519733,0.00033534053,0.0010575498,0.0011777963],"domain_scores_gemma":[0.96454805,0.023185048,0.009226894,0.00044571667,0.0021029774,0.0004912565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040348954,0.00031038316,0.0005188848,0.0050255186,0.0004354861,0.0037754418,0.00035253775,0.0007355907,0.003266263],"category_scores_gemma":[0.016788984,0.00025427662,0.0012973555,0.012131188,0.0011263395,0.0014434095,0.0015426464,0.0009803757,0.0002550334],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025097867,0.00034013824,0.87303776,0.0025641178,0.0015582284,0.00095118594,0.0029938703,0.011482196,0.00048724553,0.03741775,0.005854476,0.06080325],"study_design_scores_gemma":[0.00011774868,0.00039401147,0.93344927,0.0020353638,0.0013490609,0.000504345,0.014837703,0.0024538639,0.0014610501,0.0034901872,0.039837826,0.000069489084],"about_ca_topic_score_codex":0.03906151,"about_ca_topic_score_gemma":0.016515873,"teacher_disagreement_score":0.03906151,"about_ca_system_score_codex":0.0062460103,"about_ca_system_score_gemma":0.0035973624,"threshold_uncertainty_score":0.07766831},"labels":[],"label_agreement":null},{"id":"W4411046742","doi":"10.1007/s40259-025-00727-z","title":"Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings","year":2025,"lang":"en","type":"review","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada","funders":"Sandoz; Diakonhjemmet","keywords":"Biosimilar; Real world evidence; Intensive care medicine; Medicine; Pharmacotherapy; Internal medicine","score_opus":0.11594011786904149,"score_gpt":0.39974440582842885,"score_spread":0.2838042879593874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411046742","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008330725,0.9945973,0.0002812509,0.0017337449,0.00016958502,0.000008103784,0.000043268665,0.000003920955,0.0023297616],"genre_scores_gemma":[0.015946917,0.98079944,0.0005070297,0.0016431046,0.00048840133,0.000029614224,0.00006028283,0.000006176589,0.000519061],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778676,0.00092054845,0.00029130175,0.00023327733,0.00067048176,0.00009757768],"domain_scores_gemma":[0.9887179,0.009062322,0.0010282636,0.00016245266,0.0008933645,0.00013566091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004981851,0.00048850465,0.0010587369,0.0013971513,0.0001892659,0.0021070954,0.0007105234,0.0017936698,0.0053312825],"category_scores_gemma":[0.01385863,0.00020041472,0.0011038124,0.0022984028,0.0009489897,0.0021071436,0.0008232896,0.0028102146,0.00070680963],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005627198,0.00010574937,0.0009403808,0.030090187,0.0006285135,0.00028317978,0.00022973752,0.0009960915,0.0014586212,0.030626498,0.016530558,0.91754776],"study_design_scores_gemma":[0.00023513405,0.00093600847,0.0076025296,0.0297656,0.0011300932,0.0034443175,0.00054930046,0.0004122601,0.0024708502,0.019112874,0.9342487,0.000092397546],"about_ca_topic_score_codex":0.0008524164,"about_ca_topic_score_gemma":0.0009902192,"teacher_disagreement_score":0.0053312825,"about_ca_system_score_codex":0.0013015468,"about_ca_system_score_gemma":0.0016005681,"threshold_uncertainty_score":0.026346862},"labels":[],"label_agreement":null}]}